Download Professional Service

Lajos Pusztai, M.D., D.Phil
CURRICULUM VITAE
Date of Revision: September 27, 2016
Name:
Lajos Pusztai, M.D., D.Phil.
Appointment:
Professor, Department of Internal Medicine,
Tenured Clinical Scholar
Section of Medical Oncology
Term:
Continuous beginning August 1, 2012
School:
Yale University School of Medicine
Education:
M.D.
D.Phil.
Medicine, Semmelweis University of Medicine, 1987
Pathology/Cell Biology, Wadham College, University of Oxford, 1993
Career/Academic Appointments:
2012-present Professor of Medicine (Medical Oncology), Yale University, School of Medicine,
New Haven, CT
2009-12
Professor, Deptartment of Breast Medical Oncology, The University of Texas M.
D. Anderson Cancer Center, Houston, TX
2007-12
Member, The University of Texas Graduate School of Biomedical Sciences,
Houston, TX
2004-09
Associate Professor, Deptartmet of Breast Medical Oncology, The University of
Texas M. D. Anderson Cancer Center, Houston, TX
1999-04
Assistant Professor, Dept. of Breast Medical Oncology, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
1996-98
Fellow, Medical Oncology, The University of Texas M. D. Anderson Cancer
Center, Houston, TX
1993-96
Intern Resident, Internal Medicine, University of Rochester, St. Mary’s Hospital,
New York, NY
1989-93
Research Fellow, John Radcliffe Hospital, Oxford, UK
1987-88
Postdoctoral Research Assistant, Hungarian Academy of Sciences, Budapest,
Hungary
Administrative Positions:
2012-present Chief of Breast Medical Oncology (http://medicine.yale.edu/lab/pusztai/people/),
Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT
2012-present Co-Director, Yale Cancer Center, Genetics, Genomics and Epigenetics Program,
New Haven, CT
2010
Member, Fifth Annual Faculty Recognition and Awards Program Review Board,
University of Texas M. D. Anderson Cancer Center, Houston, TX
1
Lajos Pusztai, M.D., D.Phil
2009-11
1995-96
Member, Faculty Senate, The University of Texas M. D. Anderson Cancer
Center, Houston, TX
President, Residency Program Steering Committee, Dept. of Internal Medicine,
St. Mary’s Hospital, Rochester, NY
Board Certification:
American Board of Internal Medicine, Certification, 1996
Subspecialty Board of Medical Oncology, Certification, 1999, Recertification, 2011
Professional Honors & Recognition:
International/National/Regional
2016: Komen Scholar, Susan Komen Foundation for the Cure, Dallas, TX
2015: Thomson Reuters Highly Cited Reseacher (top 1% of most cited investigator in
Clinical Medicine)
2008: ASCO Cancer Foundation Advanced Clinical Research Award, American Society of
Clinical Oncology
2003: Elected Fellow, American College of Physicians
2001: Career Development Award, US Department of Defense Breast Cancer Research
Program
1998: Smith Kline Beecham Travel Award, National Oncology Fellows Forum
1989: Soros Scholarship, Soros Foundation, New York, NY
University
2015 M.A. (Priv) Yale University
2011: The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, The
University of Texas M. D. Anderson Cancer Center
2007: Distinguished Alumnus Award, The University of Texas M. D. Anderson Cancer Center
2004: Aventis Drug Development Award, The University of Texas M. D. Anderson Cancer
Center
2003: Outstanding Educator Award, The University of Texas M. D. Anderson Cancer Center
1997: Clinical Trainee Research Award, The University of Texas M. D. Anderson Cancer
Center
1992: Overseas Research Students Award, University of Oxford
1987: Graduate Research Award, The Dean of Semmelweis University of Medicine
Grant /Clinical Trials History:
Current Grants
Agency: NCI
I.D.: P30CA016359
Title: “Whole exome sequencing of pre-treatment and residual cancer samples from the
randomized neoadjuvant NeoALTTO clinical trial for early stage HER2-positve breast cancer”
PI: Lajos Pusztai, M.D., D.Phil
2
Lajos Pusztai, M.D., D.Phil
Role: Prinicipal Investigator
Percent effort: 10%
Total cost: $484,876
Project Period: 09/01/2016 – 08/31/2017
Agency: Susan G. Komen
I.D.: Komen Leadership Grant SAC160076
Title: “Immunological characterization of primary metastatic breast cancer”
PI: Lajos Pusztai, M.D., D.Phil
Role: Prinicipal Investigator
Percent effort: As much as needed to accomplish the goals
Total cost: $600,000
Project Period: 05/01/2016 – 04/31/2019
Agency: Breast Cancer Research Foundation
ID#: Annual award since 2003
Title: “Characterization of intra-tumor heterogeneity in breast cancer and its clinical
implications”
PI: Lajos Pusztai, MD, D.Phil
Percent Effort: 10%
Annual Direct Costs: $250,000
Performance Period: 10/01/2003-09/30/2017
Agency: The Hope Foundation/SWOG
I.D.: ITSC Exploratory Pilot Project
Title: Genomic Analysis of Inflammatory Breast Cancer (IBC) in SWOG S0800
Clinical Trial Tissues to Identify Molecular Alterations that Underlie the
Aggressive Biology of IBC and Could Lead to the Development of New
Diagnostic Tests and Therapeutic Interventions
PI: Lajos Pusztai, M.D., D.Phil
Percent effort: as needed
Total Cost: $48,628
Performance Period: 2016
Agency: Department of Defense Breast Cancer Research Program
I.D. #: Era of Hope Scholar Award BC141326
Title: “Epigenetic mechanisms of breast cancer metastasis”
PI: Yan, Qin
Role: Co-Investigator
Percent Effort: 1%
Total Cost: $2,499,999
Project Period: 05/01/2015-04/30/2020
Agency:
Title:
PI:
NIH/NCI U10 CA180826-01
YCC Cooperative Group Grant
Howard Hochster, M.D.
3
Lajos Pusztai, M.D., D.Phil
Role:
Co-Investigator
Percent Effort: 1%
Annual Direct Costs: $344,918
Performance Period: 03/01/2014-02/28/2018
Agency: NIH/NCI 2P30 CA16359-34
Title:
Cancer Center Support Grant (CCSG)
PI:
Thomas Lynch, M.D.
Role:
Co-Investigator
Percent Effort: 1%
Annual Direct Costs: $1,330.934
Performance Period: 08/01/2013-07/31/2018
Current Clinical Trials
Agency: NCI-Southeest Oncology Group
ID: S1207
Title:Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant
Endocrine Therapy +/- One Year of everolimus in Patients with High-Risk, Hormone ReceptorPositive AND HER2/neu Negative Breast Cancer.
Percent Effort: N/A
National Translational Research PI: Lajos Pusztai, MD
Total cost: N/A
Project period: 4 years
Agency: Astrazeneca
I.D.:
Title: Single Arm Neoadjuvant Study of MEDI4736 anti-PD-L1 Antibody Concomitant with
Weekly Nab-paclitaxel followd by FAC Chemotherapy for Clinical Stage I-III Triple Receptor
Negative Breast Cancer to Improve Pathologic Complete Resonse Rate.
Percent Effort: NA
P.I.: Lajos Pusztai, M.D.
Total costs for project period: $638,270
Project period: 4 years
Agency: Merck
I.D.: MK-3475-068
Title: A Phase II Clincial Trial of Pembrolizumbab (MK-3475) as Monotherapy for Metastic
Triple Negative Breast Cancer (mTNBC) – (Keynote-086)”
P.I.: Lajos Pusztai, M.D.
Percent effort: NA
Total costs for project period: $1,721.321
Project period: 24 months
Agency:
Merck
4
Lajos Pusztai, M.D., D.Phil
I.D.#
1306012177
Title: “A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
P.I.: Lajos Pusztai, M.D.
Percent effort: NA
Total costs for project period: $ 2, 052 240
Project period: 24 months
Agency: Foundation Medicine
I.D.#
1210010985
Title: Molecular Analysis Prior to Investigational Therapy
P.I.: Lajos Pusztai, M.D.
Percent effort: 5%
Total costs for project period: $ 800,000 (provided in the form of free molecular testing)
Project period:
Agency: Genentech
I.D.# ML28772
Title: Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered
Concomitantly with Weekly Paclitaxel and FEC for Clinical Stage I-III Her2-Positive Breast
Cancer
P.I.: Lajos Pusztai, M.D.
Percent effort: 1%
Total costs for project period: $ 179,200
Project period: 4/3/13 – 4/2/15
Agency: Genentech
I.D.#
Title: An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability
of GDC-00320in Patients with Locally Advanced or Metastatic Solid Tumors in Combination
with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone ReceptorPositive Breast Cancer
P.I.: Lajos Pusztai, M.D.
Percent effort: 1%
Total costs for project period: $ 6,785 819
Project period: 6/1/2013-6/1/2015
Agency:
I.D.#
Title:
Seattle Genetics, Inc.
SC1307BRE007
A Phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of
SGN-LIV1A in patients with LIV-1-positive metstatic breast cancer.
P.I.: Lajos Pusztai, M.D.
Percent effort: NA
Total costs for project period: $ 24,330 per patient max 10 pts
Project period: 6/1/2014-6/1/2015
5
Lajos Pusztai, M.D., D.Phil
Past Grants
Agency: University of Michigan
I.D. #
UM: 13-PAF06331
Title: Correlative science funding for SWOG S0800 clinical trial specimens
Total Cost for project period: $50,000
Project period:
10/01/2014-5/1/2016
Agency:
ID#:
Title:
Breast Cancer Research Foundation
Annual Award to D.R.
“Whole exome sequencing of pre-treatment, Day-14 and residual cancer
samples from the NeoALTO clinical trial”
PI:
David Rimm, MD, PhD
Co-PI:
Lajos Pusztai, MD, D.Phil
Percent Effort: 5%
Annual Direct Costs:
$ 239,448
Performance Period:10/01/2012-09/30/2015
Agency: Lion Heart Foundation
I.D. #
Pilot Grant
Title:
“Development of a novel antibody-based therapy for triple negative breast cancer
that targets low density lipoprotein receptor-related protein 8 (LRP8)”
Total Cost for project period: $11,560
Project period:
01/01/2014-12/31/2014
Agency: Department of Defense/CDMRP
I.D.:
Predoctoral Traineeship Award – University of Texas M.D. Anderson Cancer Center
Title:
“Identification of novel therapeutic targets for triple-negative breast cancer”
P.I.:
Christine Shiang, PhD student, Graduate Research Assistant
Role on project: Mentor
Percent effort: 2%
Total costs for project period: $129,600
Project period: 12/1/2010 - 12/31/2013
Agency: The Randalls Foundation
I.D.#
Established Investigator Grant
Title:
“National I-Spy Trial II”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $ 300,000
Project period: 4/10/2012 – 4/10/2013
Agency:
I.D.:
Title:
AstraZeneca
Established Investigator Grant
“Evaluation of molecular marker-driven patient selection strategy for AZD6244 in a
prospective clinical trial and pre-clinical development of rational combinations of
biologically targeted drugs based on molecular analysis of human breast cancers”
6
Lajos Pusztai, M.D., D.Phil
P.I.:
Lajos Pusztai, M.D.
Percent effort: 5%
Total costs for project period: $309,060
Project period: 8/1/2010 - 7/31/2012
Agency: Ron and Tycha Stading Breast Cancer Fund
ID:
Philanthropic donation
Title:
“Breast Cancer Personalized Medicine Program”
PI:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs: $ 645,000
Project period: 1/12/2011 - 7/31/2012
Agency:
I.D.:
Title:
Commonwealth Foundation for Cancer Research
Established Investigator Grant
“Prospective evaluation of the clinical utility of genomic predictive markers for
asatinib in a parallel, multi-arm phase II clinical trial for metastatic breast cancer”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $359,600
Project period: 11/1/2008-10/31/2011
Agency:
I.D.:
Title:
American Society of Clinical Oncology
Advanced Clinical Research Award
“Prospective evaluation of the clinical utility of several different genomic predictive
markers in a parallel, multi-arm, two-step, phase II clinical trial program”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 9%
Total costs for project period: $450,000
Project period: 7/1/2008-6/30/2011
Agency: NIH/NCI
I.D.#
R01 CA12199401
Title:
“The P13K/PTEN/AKT signal transduction cascade in breast cancer”
P.I.:
Ana M. Gonzalez-Angulo, M.D.
Co-Investigator:
Lajos Pusztai, M.D.
Percent effort: 5%
Direct costs per year: $144,493
Total costs for project period: $722,467
Project period: 7/1/2006-12/31/2011
Agency:
I.D.#
Title:
P.I.:
American Society of Clinical Oncology
Established Investigator Grant
“The P13K/PTEN/AKT signal transduction cascade as a predictor for response to
therapy and therapeutic target in breast cancer”
Ana M. Gonzalez-Angulo
7
Lajos Pusztai, M.D., D.Phil
Co-Investigator: Lajos Pusztai, M.D.
Percent effort: 5%
Direct costs per year: $48,164
Total costs for project period: $168,507
Project period: 7/1/2006-6/30/2011
Agency: The Randalls Foundation
I.D.#
Established Investigator Grant
Title:
“National I-Spy I Trial gene expression profiling sub-project”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $264,000
Project period: 03/31/2010 – 02/28/2011
Agency: Randalls Food Market
I.D.#
Established Investigator Grant
Title:
“Breast Cancer Pharmacogenomic Research Program”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $125,000
Project period: 04/28/2009 – 03/27/2010
Agency:
I.D.:
Title:
Susan G. Komen Breast Cancer Foundation
Established Investigator Grant
“Prospective evaluation of molecular triaging with pharmacogenomic tests to
select neoadjuvant treatment, Susan G. Komen Breast Cancer Foundation”
P.I.:
Fraser Symmans, M.D.
Co-Investigator: Lajos Pusztai, M.D.
Percent effort: 5%
Total costs for project period: $1,000,000
Project period: 5/1/2008-4/30/2010
Agency:
I.D.:
Title:
The University of Texas M. D. Anderson Cancer Center
Established Investigator Grant
“Identification of novel therapeutic targets for triple-negative breast cancers
through the analysis of human breast cancer gene expression data”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 1%
Total costs for project period: $50,000
Project period: 9/1/2008-8/31/2010
Agency: NIH/NCI
I.D.#
1 R01 CA11299-01
Title:
“Targeting mTOR for cancer therapy”
P.I.:
Funda Meric-Bernstam, M.D.
Co-Investigator: Lajos Pusztai, M.D.
8
Lajos Pusztai, M.D., D.Phil
Percent effort: 1%
Total costs for project period: $1,230,000
Project period: 01/01/2005 – 12/31/2010
Agency: NIH/NCI
I.D.#
R03HG004005
Title:
“Economic evaluations of emerging genomic tests for early stage breast cancer”
P.I.:
Tina Shi, Ph.D.
Co-Investigator: Lajos Pusztai, M.D.
Percent effort: 20%
Total costs for project period: $250,000
Project period: 10/31/2008 – 04/30/2009
Agency: NIH/NCI
I.D.#
1 R21 CA118156-01A1
Title:
“ER reporter genes to predict response to endocrine therapy”
P.I.:
Fraser Symmans, M.D.
Co-Investigator: Lajos Pusztai, M.D.
Percent effort: 3%
Total costs for project period: $400,575
Project period: 09/01/2006 – 08/31/2008
Agency: NIH/NCI
I.D.#
1 R21 CA12024801
Title:
“Functional proteomics and response to preoperative therapy in breast cancer”
P.I.:
Ana M. Gonzalez-Angulo, M.D.
Co-Investigator: Lajos Pusztai, M.D.
Percent effort: 5%
Total costs for project period: $337,500
Project period: 04/01/2006 – 03/31/2008
Agency:
I.D.#
Title:
NIH/NCI
1 R01 CA106290-03
“Development and validation of gene-expression profile-based tests that predict
pathologic complete response to preoperative chemotherapy for breast cancer”
P.I.:
Lajos Pusztai, M.D.
Percent effort: 22.5%
Total costs for project period: $679,500
Project period: 02/01/2004 – 03/31/2008
Agency:
I.D.#
Title:
P.I.:
The University of Texas M. D. Anderson Cancer Center
Investigator Grant, Goodwin Funds
“Randomized clinical trial to evaluate the predictive accuracy of a gene expression
profile-based test to select patients for preoperative taxane/anthracycline
chemotherapy for stage I-III breast cancer”
Lajos Pusztai, M.D.
9
Lajos Pusztai, M.D., D.Phil
Percent effort: 5%
Total costs for project period: $95,250
Project period: 05/24/2006 – 05/23/2007
Past Clinical Trials
Agency: The University of Texas M.D. Anderson Cancer Center and the Ron and Tyda
Stading Family Gift Donation
I.D.#
P.I.:
Lajos Pusztai, M.D.
Title:
“Breast cancer evaluation and targeted investigational therapy - Protocol LAB110337”
Percent effort: 10%
Total costs: $ 645,000
Project period: 1/12/2011 - 7/31/2012
Agency:
I.D.#
P.I.:
Title:
National Institutes of Health Foundation and The Randalls Foundation
(NIHF)
Lajos Pusztai, M.D.
“Investigation of serial studies to predict your therapeutic response with imaging and
molecular analysis 2 (I-SPY II)” - Protocol 2010-0145
Percent effort: 10%
Total costs for project period: $ 300,000
Project period: 4/10/2012 – 4/10/2012
Agency:
I.D.#
Co-PI:
Title:
Susan G. Komen Foundation
Agency:
I.D.#
P.I.:
Title:
Bristol Myers Squib
Agency:
I.D.#
The University of Texas M. D. Anderson Cancer Center
Aventis Drug Development Award
Lajos Pusztai, M.D./W. Fraser Symmans, M.D.
“Molecular triaging of newly diagnosed breast cancer for preoperative therapies” Protocol 2008-0765
Percent effort: 10%
Total costs for project period: $1,000,000
Project period: 2009-2012
Lajos Pusztai, M.D.
“Personalized treatment selection for Dasatinib in metastatic breast cancer” - Protocol
2007-0574
Percent effort: 10%
Total costs for project period: $385,710
Project period: 2007−2012
10
Lajos Pusztai, M.D., D.Phil
“Discovery of molecular predictors of response to preoperative FEC chemotherapy
and validation of novel markers of benefit from adjuvant anthracycline therapy for
breast cancer” Protocol LAB05-0947
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $50,576.95
Project period: 2006-2007
Title:
Agency:
I.D.#
Title:
Southwestern Oncology Group
NCI/CTEP, Genentech
“Randomized study of weekly vinorelbine (Navelbine) alone versus vinorelbine plus
trastuzumab (Herceptin) for patients with HER-2-positive metastatic breast cancer
who have failed previous taxane/trastuzumab combination therapy” Protocol
SWOGS-0347
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $14,457.60
Project period: 2004-2006
Agency:
I.D.#
Title:
Dee Simmons Family Fund
philanthropic donation
“Transcriptional profiling of primary breast cancer to define predictors of response to
different chemotherapy regimens” Protocol 2003-0321
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $26,325
Project period: 2003-2006
Agency:
I.D.#
Title:
Xanthus Life Sciences
clinical trial funding
“Amonafide: Individual phenotype-adjusted chemotherapy for women with
metastatic breast cancer who have progressed despite prior chemotherapy” Protocol
DM03-0081
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $100,984
Project period: 2003-2005
Agency:
I.D.#
Title:
Department of Defense
Department of Defense Career Development Award
“Exploratory study to assess expression of sigma 1 receptor in breast cancer” Protocol
LAB02-528
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $241,000
Project period: 2001-2005
11
Lajos Pusztai, M.D., D.Phil
Agency:
I.D.#
Title:
AstraZeneca
clinical trial funding
“A non-randomized, open label, phase II, multi-center trial of ZD1839 (Iressa) 500mg
daily in patients with advanced breast cancer” Protocol DM01-165
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $99,804
Project period: 2001-2002
Agency:
I.D.#
Title:
Xenova, Inc.
clinical trial funding
“Phase II study to evaluate XR9576, a selective MDR-1 inhibitor in chemotherapy
resistant advanced breast cancer” Protocol ID01-165
P.I.:
Lajos Pusztai, M.D.
Percent effort: 10%
Total costs for project period: $175,000
Project period: 2001−2002
Agency:
I.D.#
P.I.:
Title:
Cell Pathways Inc.
clinical trial funding
Lajos Pusztai, M.D.
“Phase I-II study to evaluate safety, efficacy and pharmacokinetic interactions
between capecitabine (XELODA) and exisulind (AptosynTM) in patients with
metastatic breast cancer” Protocol ID00-049
Percent effort: 10%
Total costs for project period: $6,286.88/patient enrolled
Project period: 2000-2001
Pending Grants
Agency: V-Foundation
I.D.#
Translational Research Award
P.I.:
Lajos Pusztai, M.D.
Title:
“Immune biological differences between Triple Negative Breast Cancer in African
American and non-African American women and potential immunotherapy opportunities to
improve outcome”
Percent effort: 5%
Total costs for project period: $ 600,000
Project period: 2016-2019
Invited Speaking Engagements, Presentations, Symposia & Workshops
International/National
12
Lajos Pusztai, M.D., D.Phil
2016 26th Annual Interdisciplinary Breast Cancer Conference: “Genomic Biomarkers for
Breast Cancer”, Las Vegas, NV.
2016 26th Annual Interdisciplinary Breast Cancer Conference: “Emerging Paradigm Shifts of
Therapy in Early Stage Breast Cancer”, Las Vegas, NV.
2016 The 21st Annual Multidisciplinary Symposium on Breast Disease: “Immunotherapy of
Breast Cancer” Amelia Island, FL.
2016 Fudan University Life Sciences Institute and Shanghai Cancer Center: “Emerging New
Concepts in Breast Cancer Genomics”, Shanghai, China
2015 San Antonio Breast Cancer Symposium: “Whole exome sequencing of pre-treatment
biopsies from the neoALTTO Trial to identify DNA aberrations associated with response
to HER2-targeted therapies”, San Antonio, TX
2015 XXXI Annual Meeting of the Hungarian Oncologists’s Association (MOT):
“Immunotherapy of Breast Cancer”. Budapest, Hungary
2015 European Cancer Congress, Satelite Symposium: “Immunotherapy in Triple-Negative
Breast Cancer; Results and Ongoing Clinical Trials”, Vienna, Austria
2015
14th Annual International Congress on the Future of Breast Cancer: “Novel
Diagnostics: Emerging Clinical Utility Focus on the Genome”. Huntington Beach,
CA
2015 FV Hospital Breast Cancer Multidisiplinary Treatment Symposium: “Systemic Therapy
of Breast cancer: When and How?” Ho Chi Minh City, Vietnam
2015 Bach Mai Hospital Breast Cancer Multidisciplinary Course: “Invasive Breast Carcinoma
Management in 2015, Systemic Therapy: When and How?” Hanoi, Vietnam
2015 IMPAKT Breast Cancer Conference: “Therapeutic implications of mutational evolution
in breast cancer” Brussels, Belgium
2015 Belsky-Moranis Lecture NYU Langone Medical Center Grand Rounds: Divide and
Conquer; the end game in sight for breast center”, New York, NY
2015
Symposium Cancer du Sein: “Breast Cancer Genomics”, Paris, France
2014
Southwest Oncology Fall Group Meeting: “Adjuvant PDL-1 Antibody Therapy for High
Risk Triple Negative Breast Cancer”, Chicago, IL
2014 International Istanbul Breast Cancer Conference: “Role of Neoadjuvant Chemotherapy In
The Post ALTTO Era”, Istanbul Turkey
13
Lajos Pusztai, M.D., D.Phil
2014
ASCO Breast Cancer Symposium: “Next Generation Sequencing for Determining
Treatment in Breast Cancer: Ready for: Prime Time?” San Francisco, CA
2014: II Congreso Nacional De Mastologia: Neoadjuvant treastment of breast cancer”,
Cancun Mexico
2014: ASCO Annual Meeting, American Society of Clinical Oncology (ASCO),
Invited speaker/Discussant, Chicago, IL
2014: Annual Meeting, American Association for Cancer Research (AACR), Session
Chair; San Diego, CA
2013: 37th Annual Breast Cancer Symposium, Discussant (S5-01 to S5-02) San Antonio, TX
2013: 2nd Annual Conference Global Biomarkers Consortium: Optimal, Value-Based Use of
Molecular Biomarkers in Oncology: The Expert’s Perspective on How I Treat My
Patients, Breast Cancer, Boston, MA
2013: Breast Cancer Symposium (ASCO) meeting: “Surrogate Markers versus Real
Moleculasr Profiling”, San Francisco, CA
2013: Annual American Society of Clinical Oncology (ASCO) Meeting: “Using the Metastatic
Tumor Molecular Profile to Tailor Treatment”, Chicago, IL
2013: Controversies in Breast Cancer. “Validation and interpretation of biomarkers”, Tata
Medical Center, Kolkata, India
2013: 13th St. Gallen International Breast Cancer Conference 2013. “Influence of genomics on
adjuvant treatments for pre-invasive and invasive breast cancer”, St. Gallen, Switzerland.
2013: Breast Cancer Conference. “Challenges and opportunities in breast cancer clinical trial in
the genomic era”, Okayama, Japan
2013: Translational Research Summit. “Divide and conquer: challenges and opportuniites in
breast cancer clinical trial in the genomic era”, Tokyo, Japan.
2013: Annual Meeting, American Association for Cancer Research (AACR), Poster
presentation: “Metabolic vulnerability of breast cancer based on shifts in the expression
of metabolic enzyme isoforms”, Washington, DC.
2013: 6th Annual Safeway Breast Cancer Retreat, “Biomarker development in the neoadjuvant
treatment setting of early stage breast cancer and its implications for the recent FDA
guidance policy”, Washington, DC.
14
Lajos Pusztai, M.D., D.Phil
2012: CTRC-AACR San Antonio Breast Cancer Symposium. “Use of genomic tests in routine
practice and clinical research in metastatic breast cancer”, San Antonio, Texas
2012: XII Michelangelo Foundation Seminar: “Prediction of benefit from response, pCR and
biomarkers and the challenge of breast cancer heterogeneity”, Milan, Italy
2012: ESMO 2012 Congress: “ER+/HER2+ and ER-/HER2+ breast cancers are molecularly
distinct but immune gene signatures are prognostic and predictive in both groups”,
Vienna, Austria
2012: Annual ASCO Meeting: “Use of next-generation sequencing (NGS) to detect high
frequency of targetable alterations in primary and metastatic breast cancer (MBC)”,
American Society of Clinical Oncology, Chicago, IL
2012: 59th Karolinska Institutet Nobel Conference, Stockholm, Sweden, Integrated analysis
of gene expression, DNA copy number and mutation data for molecular diagnostics of
breast cancer”
2012: 2nd Pavia Update on Breast Cancer Symposium, Nadirex International srl, Pavia, Italy,
Speaker, “Breast cancer beyond molecular classification”
2012: AACR Annual Meeting: “Genomic signatures and predictive biomarkers in breast cancer:
Challenges and controversies”, American Association for Cancer Research, Chicago, IL
2012: Advances in Breast Cancer Conference: “How do we know if a biomarker is credible?”
Doctaforum Congresos Reuniones Cientificas, Madrid, Spain
2011: 33rd Annual San Antonio Breast Cancer Symposium, UT Health Science Center, San
Antonio, TX, Speaker, “Protein kinase mutation patterns in human breast cancer”
2011: VI Congress Attualita in Senologia: “Molecular analysis of breast cancer to select
patients for targeted therapies”, O.I.C. Srl Firence, Florence, Italy
2011: IX Madrid Breast Cancer Conference: “Gene pathways associated with prognosis and
chemotherapy sensitivity in different molecular subtypes", Fundacion MMA, Madrid,
Spain
2011: Combating Breast Cancer Conference: “Beyond molecular class”, IF Kongress
Management GMBH, Munich, Germany
2011: The Mater 14th International Breast Cancer Meeting: “Lessons learned from neoadjuvant
chemotherapy”, Mater Misericordiae University Hospital, Dublin, Ireland
2011: 16th ECCO - 36th ESMO Multidisciplinary Cancer Congress: “Role of gene expression
profiling for biomarker discovery”, The European Cancer Organization, Stockholm,
Sweden
15
Lajos Pusztai, M.D., D.Phil
2011: Nordic HER2 State of the Art Meeting: “Next generation HER2 and other HER2 family
member sequencing results”, Roche AB, Stockholm, Sweden
2011: IMPAKT Breast Cancer Conference: “New technologies:”, ESMO Congress, Brussels,
Belgium
2011: 102nd Annual AACR Meeting: “A decade of transcriptomic analysis of breast cancer:
What have you learned”, American Association for Cancer Research, Orlando, FL
2011: Current Strategies in the Treatment of Breast Cancer Conference: “Treatment insights
based on molecular subtypes and novel diagnostics”, International Cancer Network, LLC,
Philadelphia, PA
2011: 14th National Breast Cancer Trials Meeting: “The impact of breast cancer molecular
heterogeneity on clinical trial design, interpretation and biomarker discovery”, National
Cancer Research Institute (NCRI), The Royal Marsden NHS Foundation Trust, London,
UK
2011: CNIO Frontiers Meeting: “Using human genomic data to define the next generation of
therapeutic targets for triple negative breast cancer”, Spanish National Cancer Research
Centre, Madrid, Spain
2011: XI Michelangelo Foundation Seminar: “Patient selection for endocrine therapy: Beyond
the tumor estrogen receptor status”, Fondazione IRCCS Istituto Nazionale Del Tumori,
Milan, Italy
2011: Controversies in Breast Cancer Conference: “Contributions of biomarkers to personalized
medicine”, Sultan Qaboos University Hospital, Muscat, Oman
2010: Molecular Cytopathology Congress: “Breast cancer molecular profiling”, Centro
Congressi Universita Federico II, Naples, Italy, 10/2010
2010: 7th International Consensus Conference: “Adjuvant therapy in stage I breast cancer,
including the influence of multigene assays and molecular profiling”, Kimmel Cancer
Center, Foundation of Breast and Prostate Health, Philadelphia, PA
2010: 4th International Symposium on Primary Systemic Treatment in the Management of
Operable Breast Cancer: “Pharmacogenomics to guide successful development of old and
new therapies”, Istituti Ospitalieri di Cremona, Cremona, Italy
2010: 4th Intl. Consensus Meeting on Neoadjuvant Treatment of Primary Breast Cancer” “Gene
signatures”, University Hospital Frankfurt, Biedenkopf, Germany
16
Lajos Pusztai, M.D., D.Phil
2010: Gene profiling: Role in clinical trial design and patient management, 6th Modena
International Breast Cancer Conference, Accademia Nazionale di Medicina, Modena,
Italy, 9/2010
2010: 4th Seoul Breast Cancer Symposium: “Molecular profiles to predict chemotherapy
responsiveness”, Seoul National University, Seol, Korea
2010: 2nd Worldwide Innovative Networking Symposium: ”Personalized cancer medicine
discoveries from the bench to the bedside”, Paris, France
2010: Controversies in Breast Cancer Meeting: “Molecular profiling currently offers no more
than tumour morphology and basic immunohistology”, Novartis, Pfizer, Roche,
Edinburgh, UK
2010: 46th Annual ASCO Meeting: “Gene-signature based patient selection for Dasatinib
therapy in metastatic breast cancer”, American Society of Clinical Oncology, Chicago, IL
2010: CNIO Frontiers Meeting: “Clinical trial design to prospectively test molecular markers
and patient selection strategies”, Centro Nacional de Investigaciones Oncologicas
(CNIO), Madrid, Spain
2010: Third Annual Symposium on Personalized Therapies for Breast Cancer, “PointCounterpoint 1: Genomic profiling assay tests are helpful in clinical decision making for
node-positive breast cancer”, The Oncology Learning Center, Inc., La Jolla, CA
2010: Symposia on Cancer Research: Personalized Cancer Therapy and Prevention, The
University of Texas M. D. Anderson Cancer Center, Houston, TX, Co-Chair
2010: Meet the Professor 5th Advanced Course on Breast Cancer: “Gene expression profiling is
an essential component for an appropriate management of early breast cancer”,
Accademia Nazionale di Medicina, Modena, Italy
2010: International Expert Meeting: “Integration of molecular diagnostics in clinical trials: The
problem of identification and validation”, BANSS Foundation, Biedenkopf, Germany
2010: II Multidisciplinary Meeting on Breast Cancer Management: “Pathology in the relapsing
or metastatic breast cancer patient: Should all the patients be re-biopsied?”, The
University of Texas M. D. Anderson International Spain, Madrid, Spain
2010: Controversies in Breast Cancer Meeting: “mRNA based on genomic predictors”,
University of Edinburgh, Edinburgh, UK
2010: II Multidisciplinary Meeting on Breast Cancer Management: “Molecular and
pathological predictors of response and outcome after neoadjuvant chemotherapy”, The
University of Texas M. D. Anderson International Spain, Madrid, Spain
17
Lajos Pusztai, M.D., D.Phil
2010: ECCO 15 - 34th ESMO Congress: “Genomics in early clinical trials”, European Cancer
Organisation - ECCO, Berlin, Germany
2010: Worldwide Innovative Networking in Personalized Medicine Conference: “Biomarkers to
personalize medicine”, Institut Gustave Roussy, Paris, France
2010: VIII Madrid Breast Cancer Symposium II: Advances in Genetics: “Molecular
heterogeneity of breast cancer: Implications for treatment and clinical trials”, BN&CO
Congress Management, Madrid, Spain
2010: VIII Madrid Breast Cancer Symposium VII: Management of Triple-Negative Breast
Cancer Patients: “Behavior and differences in clinical and pathological situations”,
BN&CO Congress Management, Madrid, Spain
2010: IMPACT Breast Cancer Conference: “Pharmacogenomic predictive marker discovery in
phase II clinical trials: Mission impossible”, IMPAKT Conference Secretariat, Brussels,
Belgium
2010: EORTC Annual Meeting (EGAM): “Molecular heterogeneity of breast cancer, lessons
and caveats from predictive marker discovery in neoadjuvant studies”, European
Organization for Research and Treatment of Cancer, Brussels, Belgium,
2010: 26th Annual Miami Breast Cancer Conference: “Discovery of the next set of therapeutic
targets through genomic analysis”, Physicians' Education Resource (PER), Miami, FL
2010: VII GEICAM International Symposium: “Targeted adjuvant therapy of triple negative
breast cancer”, GEICAM, Barcelona, Spain
2010: 2nd TBCI Correlative Sciences Workshop, TBCI, “Tandem, two-step Phase II design to
rapidly evaluate candidate predictors and novel drugs”, Bethesda, MD
2010: AACR Special Conference on Translation of the Cancer Genome: “Discovery of next
generation drug targets and response markers from human gene expression data”,
American Association for Cancer Research, Boston, MA
2010: Second Annual Symposium on Personalized Therapies for Breast Cancer: “Clinical
applications of gene expression profiling-based prediction of complete pathologic
response to neoadjuvant taxane/FAC chemotherapy in breast cancer, Indiana University
School of Medicine, Miami, FL
2010: The University of Texas M. D. Anderson Cancer Center, Breast Cancer Research
Program Fall Annual Retreat, Houston, TX, Chair
2008: 8th Seminar Fondazione Michelangelo: “Why results from biomarker studies and
adjuvant chemotherapy trials are so often confusing”, Fondazione IRCCS Istituto
Nazionale Del Tumori, Milan, Italy
18
Lajos Pusztai, M.D., D.Phil
2008: American College of Surgeons 94th Annual Clinical Congress: “Update on molecular
profiling in the management of breast cancer”, American College of Surgeons, San
Francisco, CA
2008: Prognosis and Prediction in Breast Cancer Congress: “Pathologic complete response
prediction results and long term survival”, Publi Creations - Partenaire du Groupe AIM,
Monte Carlo, Monaco
2008: Prognosis and Prediction in Breast Cancer Congress: “Molecular heterogeneity and
interpretation of adjuvant clinical trials”, Publi Creations - Partenaire du Groupe AIM,
Monte Carlo, Monaco
2008: Breast Cancer Symposium: “Developing predictors for neoadjuvant therapy”, American
Association of Clinical Oncology, Washington, DC
2008: Biological Basis in Breast Cancer Conference: “Pharmacogenomic predictors of response
to therapy”, CBCE, San Francisco, CA
2008: Breast Cancer Research Program Era of Hope Meeting: “Predicting drug resistance and
the efficacy of various treatment regimens”, U.S. Department of Defense, Baltimore, MA
2008: 44th Annual ASCO Meeting, American Society of Clinical Oncology, Clinical Science
Poster Discussant: “Triple-negative breast cancer: Metastatic risk and role of platinum
agents”, Chicago, IL
2008: 3rd Central European Regional Meeting: “Clinical pathology of primary systemic
therapy”, Technology Transfer in Diagnostic Pathology Breast Pathology, IAP Hungarian
Division, Visegrad, Hungary
2008: 8th Annual New Strategies in Breast Cancer Symposium: “Biology of neoadjuvant
therapies”, The Center of Biomedical Continuing Education (CBCE), Philadelphia, PA
2008: CNIO Seminar Series, Centro Nacuional de Investigacines Oncologicas (CNIO), “New
insights into breast cancer biology through analysis of human gene expression data”,
Madrid, Spain
2008: 13th Aichi Cancer Center International Symposium: “Molecular diagnostics in the
selection of therapy for early stage breast cancer: What progress have we made?”, Aichi
Cancer Center, Nagoya, Japan
2008: Preoperative Therapy in Breast Cancer Symposia: “Preoperative chemotherapy:
Opportunities for predictive marker discovery”, General Hospital Leoben, Leoben,
Austria
19
Lajos Pusztai, M.D., D.Phil
2008: 1st Annual North American Symposium on Personalized Therapies for Breast Cancer:
“Molecular predictors of response to adjuvant endocrine therapy in ER+ breast cancer”,
The Oncology Learning Center, Miami, FL
2008: 1st Annual North American Symposium on Personalized Therapies for Breast Cancer:
“Future directions in developing predictors and individualization therapy”, The Oncology
Learning Center, Miami, FL
2008: TransALTTO Committee Meeting, TransALTTO, San Antonio, TX, Co-Chairman
2008: 61st Annual Symposium on Cancer Research Systems Biology of Cancer, The University
of Texas M.D. Anderson Cancer Center, Houston, TX, Co-Chairman
2008: Television Media Live Internet Broadcast interview on personalized treatment of breast
cancer based on molecular diagnosis, 12th National Telemedicine Educational
Symposium, Shantou University Medical College, Shantou, China.
2007: 1st Belgian Symposium on the Integration of Molecular Biology Advances into
Oncology Clinical Practice, Jules Bordet Institute, Diegem, Belgium, “Microarray
technologies as prognostic and predictive tool: Still investigational or ready for use?”
2007: III International Symposium on Breast Cancer, AO Istituti Ospitalieri, Cremona, Italy,
“Pharmacogenomics as an identifier method for target therapy”
2007: AACR-NCI-EORTC International Conference, American Association of Cancer
Research, San Francisco, CA, “Integrated genomic test to aid treatment selection”
2007: Lynn Sage Breast Cancer Symposium, Robert H. Lurie Comprehensive Cancer Center of
Northwestern University, Chicago, IL, “Improving the selection of neoadjuvant therapy”
2007: 43rd Annual ASCO Meeting, American Society of Clinical Oncology, Chicago, IL,
“Breast cancer: Local-regional and adjuvant therapy”
2007: 43rd Annual ASCO Meeting, American Society of Clinical Oncology, Chicago, IL,
“Technology driven decision making in oncology”
2007: 43rd Annual ASCO Meeting, American Society of Clinical Oncology, Chicago, IL,
“Gene expression profiling to predict response to anthracyclines”
2007: VII Madrid Breast Cancer Conference, BN&CO, Congress Management, Madrid, Spain,
“Gene expression profiling as predictive factor of response to treatment”
2007: 4th Annual Breast Cancer Think Tank Meeting, New York, NY, “Use of molecular
expression to facilitate drug discovery”
20
Lajos Pusztai, M.D., D.Phil
2007: Annual AACR Meeting, American Association of Cancer Research, Los Angeles, CA,
“Novel trial design for early drug development”
2007: NCI Preoperative Therapy in Invasive Breast Cancer Meeting, NIH, Bethesda, MD,
“Molecular profiling”
2007: Bristol-Myers Squibb Satellite Symposium, Bristol-Myers Squibb, St. Gallen,
Switzerland, “Markers predicting clinical benefit from microtubule-targeting agents”
2007: Wendy and Emery Reves International Biennial Breast Cancer Symposium, Dallas, TX,
“Molecular profiling: Promises and limitations”
2007: Annual Sino-US Clinical Oncology Seminar Series sponsored by The University of
Texas M. D. Anderson Cancer Center, Guangzhou, China, “Molecular diagnostics for
selecting therapy for breast cancer”
2007: 29th San Antonio Breast Cancer Symposium, San Antonio, TX, “Microtubule associated
protein (MAP)-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy
resistance in ER-positive breast cancer”
2007: 2nd Biological Basis in Breast Cancer Conference, CBCE, Santa Monica, CA, CoChairman
2006: CNIO Symposium on Molecular Markers in Cancer Therapy: Present use and future
perspectives, Madrid, Spain, “Gene expression profile-based predictors of response to
chemotherapy”
2006: Molecular profiling for treatment decision, ESMO Congress, ESMO, Istanbul, Turkey,
10/2006
2006: 4th Breast Cancer Frontier Meeting, Tokyo, Japan, “Gene expression profile-based
predictors of response to chemotherapy”
2006: International Scientific Symposium, Paris, France, “Predictive biomarkers for the
efficacy of chemotherapy”
2006: 4th NCI/EORTC International Meeting on Cancer Molecular Markers, NIH, Stone
Mountain, GA, “Molecular signatures of response to therapy”
2006: ASCO Development of Molecular Therapeutics in Breast Cancer Conference, American
Society of Clinical Oncology, Aspen, CO, “Gene expression profiling for prediction of
response or resistance to treatment”
2006: 3rd Annual Pfizer Breast Cancer Think Tank Meeting, Pfizer, New York, NY, “Will
molecular profiling of breast cancer (stem cells) provide new targets for cancer therapy?”
21
Lajos Pusztai, M.D., D.Phil
2006: 42nd Annual ASCO Meeting, Clinical Science Symposium, American Society of Clinical
Oncology, Atlanta, GA, “Pharmacogenomic predictor of complete response to
preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy
in breast cancer”
2006: 42nd Annual ASCO Meeting, Clinical Science Symposium, American Society of Clinical
Oncology, Atlanta, GA, “Pharmacogenetics: Targeting the tumor and the patient”
2006: 97th Annual AACR Meeting, American Association for Cancer Research, Washington,
DC, “Development of a pharmacogenomic predictor of complete response to
preoperative paclitaxel-FAC chemotherapy for breast cancer”
2006: XXIII Annual Meeting of the National Cancer Institute of Mexico (INCAN), National
Cancer Institute, Puerto Vallarta, Mexico, “The use of avestin and other targeted
therapies in breast cancer”
2006: 11th Annual Multidisciplinary Symposium on Breast Disease, Jacksonville, FL, “The
emerging role of prognostic/predictive factors”
2006: 11th Annual Multidisciplinary Symposium on Breast Disease, Jacksonville, FL,
“Adjuvant aromatase inhibitor therapy for breast cancer: The current and future roles”
2006: 1st Biological Basis in Breast Cancer Conference, CBCE, San Diego, CA, Co-Chairman
2005: 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, “Affymetrix gene
chip profile predicts pathologic response to preoperative paclitaxel, 5-FU, doxorubicin
and cyclophosphamide chemotherapy”
2005: 2nd International Symposium on Cancer: New Trends in Cancer for the 21st Century,
Valencia, Spain, “Pharmacogenomics in breast cancer”
2005: 1st Annual Great Debates in Breast Cancer Meeting, Lake Tahoe Resort, NV, “New
diagnostic methods in breast cancer: Can we move beyond histology?”
2005: Grand Rounds, New York, NY, “Novel genomic tools: Clinical utility, controversies in
breast cancer adjuvant and neoadjuvant therapy”
2005: Era of Hope Department of Defense (DOD) Breast Cancer Research Program Meeting,
Philadelphia, PA, “Role of sigma receptor in breast cancer"
2005: VI Madrid Breast Cancer Conference, Madrid, Spain, “Gene-expression profile-based
predictors of response to chemotherapy”
2005: Retreat of the Breast Cancer Intergroup of North America (TBCI) Meeting, Chicago, IL,
“Gene expression and genomic profiling centers”
22
Lajos Pusztai, M.D., D.Phil
2005: Retreat of the Breast Cancer Intergroup of North America (TBCI) Meeting, Chicago, IL,
“Biomarker incubator for taxane response concept”
2005: Grand Rounds, Philadelphia, PA, “Polymorphisms and pathways: An update on
genomics in breast cancer”
2005: The Tucson Symposium, Ventana Medical Systems, Tucson, AZ, “Genomic predictive
biomarker development and validation for breast cancer: A clinical perspective”
2005: 2nd Annual Symposium: Evolving paradigms in the treatment of breast cancer, Orlando,
FL, “Gene expression profiles in predicting response”
2005: AACR Oncogenomics 2005: Dissecting cancer through genome research, San Diego,
CA, “Pharmacogenomic predictors of response to chemotherapy for breast cancer”
2005: Scripps Cancer Center Annual Conference, San Diego, CA, “Analysis of microarray data:
A primer for oncologists”
2004: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, “Microtubule
associated protein tau is a predictive marker and modulator of response to paclitaxelcontaining preoperative chemotherapy in breast cancer”
2004: NCI/FDA Workshop, NIH, Gaithersburg, MD, “Research strategies, study design and
statistical approaches to biomarker validation for cancer diagnosis and detection”
2004: 40th Annual ASCO Meeting, American Society of Clinical Oncology, Education Session,
New Orleans, “Integrating DNA microarrays into clinical practice”
2004: 12th Annual Meeting of the Japanese Breast Cancer Society, Kokura, Japan, “Gene
expression profiling of breast cancer”
2004: IBC' 3rd Annual Molecular Diagnostics, Princeton, NY, “DNA microarray analysis of
breast cancer”
2004: 4th International Workshop on Molecular Targeted Therapy of Cancer, Barcelona, Spain,
“Functional genomics and proteomics”
2004: Symposium on Genomics, Washington, DC, “New strategies in breast cancer”
2004: Evolving Paradigms in the Treatment of Breast Cancer Symposium, Orlando, FL, “Gene
expression profiles and cancer treatment”
2004: 96th Annual AACR Meeting, American Association for Cancer Research, Orlando, FL,
“Cancer Biomarkers: A clinical perspective, challenges and opportunities in the postgenomic era”
23
Lajos Pusztai, M.D., D.Phil
2004: Roche Standalone Meeting on Targeting Breast Cancer with Care, Prague, Czech
Republic, “Improving patient care through molecular diagnostics”
2003: 2nd Emerging Trends in Adjuvant Therapy of Breast Cancer Conference, New York, NY,
“Selection of optimal preoperative chemotherapy regimen based on the molecular profile
of cancer”
2003: 9th Annual Perspectives in Breast Cancer, Boston, MA, “Predictive factors orienting the
choice of chemotherapy”
2003: 2nd Annual Mini-Conference, Breast Cancer Research Foundation, New York, NY,
“Predicting response to pre-operative chemotherapy”
2003: Breast Cancer Therapeutic Options in the Post-Genomic Era Conference, Modena, Italy,
“Gene expression profiling and clinical implications”
2003: 2nd International Future of Breast Cancer Congress, Banff, Canada, “Predicting response
to neoadjuvant chemotherapy with tumor molecular analyses”
2003: 6th Annual Conference onTargeted Therapies in the Treatment of Breast Cancer, Kona,
H, “Potential and limitations of pharmacogenomics in predicting response to therapy”
2003: V Madrid Breast Cancer Conference, Madrid, Spain, “Gene-expression profile based
tests predictive of pathologic complete response to preoperative chemotherapy for breast
cancer”
2003: 39th Annual ASCO Meeting, American Society of Clinical Oncology, Chicago, IL,
“Emerging science: Prospective validation of gene expression profiling-based prediction
of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast
cancer”
2002: ASCO Molecular Therapeutics Symposium, San Diego, CA, “Gene expression profiling
of fine needle aspirations of breast cancer identifies genes associated with complete
pathologic response to neoadjuvant taxol/FAC chemotherapy”
2002: 38th Annual ASCO Meeting, American Society of Clinical Oncology, Orlando, FL,
“Correlation between HER-2 expression of breast cancer and response to neoadjuvant
chemotherapy”
2001: 33rd Annual Scientific Meeting of the Hungarian Medical Association of America,
Sarasota, FL, “Novel drugs for the treatment of breast cancer”
2001: 12th Congresso Brasileiro de Oncoloia Clinica, Florianopolis, Brazil, “Adjuvant
chemotherapy of breast cancer”
24
Lajos Pusztai, M.D., D.Phil
2001: IV Madrid Breast Cancer Conference, Madrid, Spain, “Metastatic breast cancer: New
agents in the clinic”
2001: Investigators Meeting, Cell Pathways Inc., San Francisco, CA, “Phase I-II study to
evaluate safety, efficacy and pharmacokinetic interactions between capecitabine
(XELODA) and exisulind (AptosynTM) in patients with metastatic breast cancer”
2000: Genentech Herceptin Investigators' Meeting, Charleston, SC, “Duration of herceptin
therapy in combination with cytotoxic drugs”
2000: Pharmacia COX 2 Think Tank Conference, Chicago, IL, “COX-2 inhibitors can inhibit
angiogenesis and reduce tumor growth and metastasis”
2000: 36th Annual meeting of the American Society of Clinical Oncology, New Orleans, LA,
“Gene expression profiles in normal breast epithelial cells and breast cancer”
2000: 10th International Congress on Anti-Cancer Treatment, Paris, France, “Transcriptional
profiling of breast cancer cells before and after exposure to paclitaxel (TaxolR)”
1999: Brazil-Portugal Cancer Conference, Vitoria, Brazil, “Neoadjuvant and adjuvant
chemotherapy for breast cancer”
1999: Brazil-Portugal Cancer Conference, Vitoria, Brazil, “Advances and future directions in
breast cancer”
1998: SmithKline Beecham National Medical Oncology Fellows Forum, Tucson, AZ, “Clinical
characteristics of relapse after complete clinical response (CR) induced by combination
chemotherapy in metastatic breast cancer”
1991: Society of Great Britain and Ireland, 162nd Meeting, Cambridge, Ireland, “Regulation of
breast cancer cell growth by TGFb, IFNg, IL6 and IL4”
Regional
2016 OncoLive State of Science Summit. “State of the Science in Targeted and
Immunotherapy of Breast Cancer”, New Haven, CT
2016 13th Annual Best of San Antonio; Breast Cancer Bench to Bedside“Prognostic and
Predictive Biomarkers for Precision Breast Cancer Therapy” Chicago, IL
2015 Northern New England Clinical Oncology Society:” Interpretation of Genomic
Tests: Indentifying Potential Therapies/Clinical Trials”, Portland, ME
2013: 7th Annual Translational Oncology Research Symposium: Invited speaker: “Breast
Cancer: Beyond molecular classification”, Albany, NY
25
Lajos Pusztai, M.D., D.Phil
2013: Post-San Antonio Breast Cancer Symposium. “Genomics of breast cancer”, Roslyn, New
York
2013: Jucket Distinguished Lecture Series. “Breast Cancer Genomics”, Vermont Cancer Center,
Burlington, VT
2009: Radio interview on the molecular origin of breast cancer, Kate Seremek, Producer, Reach
MD XM 160, The Channel for Medical Professionals.
Seminar Invitations from Other Institutions
2015 Perlmutter Cancer Center Research Seminar: “Biological Interpretation of multiple
genomic abnormities in cancer”, NYU Medical Center, NY
2014: Columbia University Grand Rounds: “Breast Cancer Beyond Molecular Classification:
The Next Generation of Tests and Therapeutic Strategies”, New York, NY
2014: Multidisciplinary Breast Grand Rounds: “Breast Cancer Beyond Molecular
Classification”, Massauchusetts General Hospial, Boston, MA
2013: Grand rounds Presentation: Breast Cancer beyond molecular classification”, MSKCC
Department of Pathology Sloan Kettering, New York, NY
2013 Johns Hopkins University, Annual Breast Cancer Program Retreat: “Biomarker
Development in the Neoadjuvant Treatment Setting of Early Stage Breast Cancer”,
Baltimore, MD
2013 Albert Einstein College of Medicine Grand Rounds: “Breast Cancer Beyond Molecular
classification”, New York, NY
2008: The University of Texas Graduate School of Biomedical Sciences, Human Protocol
Research Course: “Personalized cancer therapy trials: How to find the patients who
actually benefit from a given therapy?”, Houston, TX
2008: Dana-Faber Cancer Institute, DFCI SPORE Seminar: “Pharmacogenomic predictors of
response to therapy in breast cancer”, Boston, MA
2008: Netherlands Cancer Institute, Seminar: “Breast cancer pharmacogenomic program”,
Amsterdam, Netherlands
2008: Vanderbilt University, Breast Cancer Research Program Seminar: “Gene expression
based treatment selection for breast cancer: M.D. Anderson Cancer Center personalized
medicine program”, Nashville, TN
2008: Affymetrix Inc., Seminar: “DNA microarrays as potential diagnostic tools”,
Santa Clara, CA,
26
Lajos Pusztai, M.D., D.Phil
2008: US Oncology Research, Seminar: “Genomics and proteomic strategies: Implications of
clinical trial design”, Dallas, TX
2008: Karmanos Cancer Institute, Seminar: “Application of pharmacogenomics to clinical
trials”, Detroit, MI
2008:
College of Medicine University of South Florida, Seminar: “Advanced in personalized
medicine: Biochemistry and molecular biology”, Tampa, FL
2008: Indiana University Cancer Center, Seminar: “Pharmacogenomic predictors of response
and prognosis in breast cancer, breakthrough or incremental success”, Indianapolis, IN
2008: European School of Oncology/Central, European Cooperative Oncology Group, Training
Course on Breast Cancer: “Novel chemotherapies for breast cancer”, Budapest, Hungary
2008: Baylor College of Medicine, Visiting Physician Educational Program: “The
contemporary management of the patient with breast cancer”, Houston, TX
2008: Rice University, Statistics Seminar: “Mathematical biology”, Houston, TX
2000: Tumor Board Conference, Kettering Medical Center, Dayton, OH, “The role of herceptin
in the management of metastatic breast cancer”
Other Lectures at State and Local Conferences
2016 Yale ASCO Review 2016 Highlights of the Annual Meeting, New Haven, CT
2016 Yale US-China Forum: “Opportunities in Cancer Genomics”, New Haven, CT
2009: GME Core Curriculum Lecture Series, The University of Texas M. D. Anderson Cancer
Center, Trainee and Alumni Affairs, Houston, TX: “Molecular-based approach to breast
cancer”
2009: Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Division of
Cancer Medicine, Houston, TX: “A journey in high dimensional molecular space”
2009: Breast Cancer Research Program Annual Retreat, Development of Personalized Medicine
in Breast Cancer, Dept. Breast Medical Oncology, The University of Texas M. D.
Anderson Cancer Center, Houston, TX: “Genomic molecular classification”
2009: Preceptorship for Medical Oncologists from Spain: Advances in the Management of
Breast Cancer, Houston, TX: “Pharmacogenomics in breast cancer”
2009: Interdisciplinary Breast Cancer Journal Club Conference, Dept. of Breast Medical
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX:“Breast
27
Lajos Pusztai, M.D., D.Phil
cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an
immunohistochemical definition in the BCIRG 001 trial”
2009: Preceptorship for Medical Oncologists from South America, Advances in the
Management of Breast Cancer, Roche, Houston, TX: “Pharmacogenomics in breast
cancer”
2009: GU Bladder SPORE Seminar, The University of Texas M. D. Anderson Cancer Center,
Houston, TX: “Discovery of gene expression based predictors of response to therapy
from small clinical trials: Mission impossible?”
2008: New Innovative Options in the Management of Advanced Breast Cancer, CME
Organization, Breast Medical Oncology, Houston, TX: “Ixabepilone in early breast
cancer: Phase II and pivotal neoadjuvant and adjuvant trials”
2008: Breast Cancer Clinical Research Meeting, M. D. Anderson Cancer Institute for
Personalized Oncology Treatment (IPCT), The University of Texas M. D. Anderson
Cancer Center Houston, TX: “Implications for the Breast Center”
2008: Interdisciplinary Breast Cancer Journal Club Conference, Dept. of Breast Medical
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX:
Systemic Review: “Gene expression profiling assays in early-stage breast cancer”
2007: Physician's Education Resource Conference, New Development in Breast Cancer
Symposium, US Oncology, Breast Cancer Research, Houston, TX: “Update on molecular
subtypes and novel diagnostics”
2007: Interdisciplinary Breast Cancer Journal Club Conference, Dept. of Breast Medical
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX: “The
RNA revolution: Results of ENCODE project”
2007: MDACC Breast Cancer Pharmacogenomic Program, Advances in Oncology Institutional
Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Pathology,
Houston, TX: “Multigene predictors of chemotherapy response”
2007: Grand Rounds, The Division of Cancer Medicine, The University of Texas M. D.
Anderson Cancer Center, Houston, TX: “Breast cancer personalized medicine program”
2007: Preceptorship Program for Spanish Oncologists, The University of Texas M. D.
Anderson Cancer Center, Houston, TX: “Molecular classification of breast cancer”
2006: Breast Cancer Research Program Fall Retreat, Dept. of Breast Medical Oncology, The
University of Texas M. D. Anderson Cancer Center, Houston, TX: “Expression profiling
of basal-like breast cancer”
28
Lajos Pusztai, M.D., D.Phil
2006: Interdisciplinary Breast Cancer Journal Club Conference, Dept. of Breast Medical
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX: “A
multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer”
2005: 13th Annual M. D. Anderson Cancer Center Radiation Oncology Workshop, The
University of Texas M. D. Anderson Cancer Center, Round Top, TX: “Gene expression
profiling of breast cancer: A potential diagnostic and discovery tool”
2004: Grand Rounds, Dept. of Surgical Oncology, The University of Texas M. D. Anderson
Cancer Center, Houston, TX: “Gene profiling in breast cancer”
2003: Grand Rounds, Dept. of Internal Medicine, The University of Texas, Health Science
Center, Houston, TX: “Pharmacogenomics, a step towards personalized medicine”
20003: Grand Rounds, Division of Cancer Medicine, The University of Texas M. D. Anderson
Cancer Center, Houston, TX: “Clinical pharmacogenomics and pharmacoproteomics in
breast cancer”
2003: Cancer Therapeutics and Discovery Program, The University of Texas M. D. Anderson
Cancer Center, Houston, TX: “Designing integrated clinical trials for response marker
discovery with novel biologically targeted agents”
2002: Schering-Plough Pharmaceuticals Physician Education Program, The University of Texas
M. D. Anderson Cancer Center, Houston, TX: “The use and challenges of transcriptional
profiling in the diagnosis and management of breast cancer”
2002: Application of genomics and proteomics to breast cancer translational research, Breast
Cancer Research Group Summer Retreat, The University of Texas M. D. Anderson
Cancer Center, Breast Medical Oncology, Houston, TX
2002: Grand Rounds, Division of Radiation Oncology, The University of Texas M. D.
Anderson Cancer Center, Houston, TX: “cDNA microarrays, a new tool in the clinic to
learn about breast cancer”
2001: The University of Texas M. D. Anderson Cancer Center, Dept. of Thoracic Head/Neck
Medical Oncology Seminar, Houston, TX: “Gene expression profiles obtained from fine
needle aspiration of breast cancer: Has pathology become an obsolete field of study?”
2001: Breast Cancer Clinical Research Meeting, The University of Texas M. D. Anderson
Cancer Center, Houston, TX: “The prognostic value of knowing all human genes in
breast cancer”
2001: Medical Fellows, The University of Texas M. D. Anderson Cancer Center, Houston, TX:
“Translational research opportunities in breast cancer”
29
Lajos Pusztai, M.D., D.Phil
2001: Houston Forum on Cancer Genomics and Informatics, The University of Texas M. D.
Anderson Cancer Center, Houston, TX: “Gene expression profiles obtained from single
passage fine needle aspirations (FNA) of breast cancer and clinicopathologic parameters”
Professional Service:
Peer Review Groups/Grant Study Sections
2015-2016
Co-Chair, AACR Clinical and Translational Research Fellowships Scientific
Review Committee.
2015
Member, Clinical and Translational Cancer Research Grants Scientific Review
Committee. American Association of Cancer Research (AACR)
2015
Member, 2015 San Antonio Breast Cancer Symposium, Abstract Review
Committee
2015
NIH Cancer Etiology Study Section, Ad Hoc member of “Genetic Basis of
Healthcare Disparities ZRG1 OBT-K (55)” , Nov12-13, 2015 [PAR 15-053,
(R21), PAR 15-092 (R21), PAR 15-093 (R01)].
2014
Chair, Research Productivity Assesment External Review Panel, University of
Tampere, School of Medicine, Health Sciences and Biomedical Technology
Institute, Finland
2014
Review of Miguel Quintela Fandino, Breast Cancer Clinical Research Unit
(BCCRRU), Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
2013
Member, Abstract Selection Committee for Predictive Markers, San Antonio
Breast Cancer Symposium
2005-present Member, NIH Breast Cancer DataMart Steering Committee, National Institutes of
Health (NIH)
2010-2012
Member, I-SPY2 Agent Selection Committee, National Institutes of Health (NIH)
2008-2010
Grant Reviewer, International Ethnic Research Initiative, GlaxoSmithKline
Oncology
2007-2010
Member, Steering Committee, Clinical Working Group, US Food and Drug
Administration Microarray Quality Control Assessment Project (MAQC)
2007-2008
Grant Reviewer, King Baudoiun Foundation, Belgium
2007
Grant Reviewer, Framework-7 Clinical-Omics Projects, European Commission
2004
Member, Clinical Trials and Awards Committee, Cancer Research UK
2004
Grant Reviewer, Italian Association for Cancer Research (IACR)
2004
Grant Reviewer, Research Funding and Policy Division, Health Research Board,
Ireland
2004
Grant Reviewer, Research Grants Council, RGC of Hong Kong
2002-05
Member, Study Section Review Committee for Clinical, Translational and
Population based projects of M. D. Anderson Institutional Research Grant
Program, The University of Texas M. D. Anderson Cancer Center
Journal Service:
Editorial Boards
2014-present
Associate Editor, Journal National Cancer Institute (JNCI), OUP
2009-present
Member, Editorial Board, Pathol Oncol Res, Springer
30
Lajos Pusztai, M.D., D.Phil
2007-present
2006-present
2004-present
2004-present
2004-present
2008-2009
Reviewer
2011-present
2010-present
2008-present
2004-present
2004-present
2004-present
2004-present
2004-present
2004-present
2004-present
Member, Editorial Board, British Journal of Cancer (former Clinical Section
Editor from 2007-2015), Nature Publishing Group
Member, Editorial Board, Drug Resistant Updates, Elsevier Ltd.,
Member, Editorial Board, Expert Opinion on Pharmacotherapy, Ashley
Publications Ltd
Member, Editorial Board, Oncomol (Gene expression data repository),
BioMed Central Ltd
Member, Editorial Board, Personalized Medicine, Future Medicine Ltd
Section Editor, Current Breast Cancer Reports, Current Medicine Group,
LLC
New England Journal of Medicine
Nature Medicine
Cancer Cell
The Lancet
Nature Biotechnology
Journal of National Cancer Institute
Journal of Clinical Oncology
Clinical Cancer Research
Cancer
British Journal of Cancer
Professional Service for Professional Organizations:
2016Member, Board of Directors, The HOPE Foundation, SWOG ,Ann Arbor, MI
2016-2019
Member, ASCO Cancer Research Committee
2016-present Member, ASCO, TAPUR trial Molecular Tumor Board
2015
Member, Scienfic Organization Committee, Promises and challenges of
developing new drugs in oncology, Milan, Italy.
2015
Faculty for ASCO University Journal Club in Breast Cancer
2015-present Member of the Data Safety Monitoring Committee, Protocol CP-MGAH22-04. A
Phase 3, “Randomized Study of Margetuximab Plus Chemotherapy vs.
Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+
Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies
and Require Systemic Treatment” MacroGenics Inc. 2012-present Chairman,
DataSafety Monitoring Board. OPTIMA trial Cancer Research UK
2015-present Honorary Member, Hungarian Oncologists Association (Magyar Onkologiai
Trasasag) Budapest
2014-present Member of the Data Safety Monitoring Committee of the “Phase 2, randomized,
open-label, multicenter, safety and efficacy study of oral lucitanib in patients with
FGF aberrant metastatic breast cancer” trial by Clovis Oncology, Inc.
2014-present Member of the External Advisory Board of the “Clinical study of treatmentrelated chronic toxicity in women with localized breast cancer (CANTO)” project
conducted by Unicancer in France.
2008-present Member, Correlative Sciences Committee, North American Breast Cancer Group
(NABCG)
31
Lajos Pusztai, M.D., D.Phil
2008-present Member, Breast Cancer Biomarker Committee, Southwest Oncologic Group
(SWOG)
2008-present Co-chair, TransALTTO Committee, Breast International Group (BIG)
2007-present Member, Scientific Advisory Committee, The Breast Cancer Research
Foundation (BCRF)
2003-present Fellow, American College of Physicians
2003-present Member, Southwest Oncologic Group
1997-present Member, American Association of Cancer Research (AACR)
1997-present Member, American Society of Clinical Oncology (ASCO)
2009-2014
Member, Breast Cancer Steering Committee, North American Breast Cancer
Group (NABCG)
2013
Member, Department of Defense Breast Cancer Idea Award Review Committee
2011
Chair, 2011 Advanced Clinical Research Award Review Subcommittee, Conquer
Cancer Foundation, American Association of Cancer Research (AACR)
2004
Co-Founder, Nuvera Biosciences
2001-2004
Member, Scientific Advisory Board, Rimonest Ltd.
2000-2005
Medical Expert Consultant, Medical Directions, Inc.
2000-2005
Member of the Council of Healthcare Advisors, The Gerson Lehrman Group Inc.
The University of Texas M. D. Anderson Cancer Center Service
2011
2011
2010-2012
2007-2012
2007
2001-2004
2000−2003
1999-2012
1999-2003
Search Committee Member, Quantitative Sciences Division Head Search
Search Committee Member, Pathology Chair Search
Member, Steering Committee for Institute of Personalized Advanced Cancer
Therapy
Member, Breast Serum/Plasma/DNA Bank Oversight Committee
Member, Bioinformatics and Computational Biology Chair Search Committee
Member, Clinical & Translational Research Center (CTRC) Review Committee
Member, Research Funding Oversight Committee of the Institutional Research
Grants Program
Education of Medical Oncology Fellows, Training Program
Member, Division of Medicine Research Sub-Committee
Yale University Service
Departmental Committees:
2014-present Member, Board of Permanent Officers of Yale School of Medicine
2014-present Member, Senior Appointments and Promotions Committee, Yale School of
Medicine
2012-present Member, Executive Committee, Yale Cancer Center
2012-present Member, Medical Oncology Physicians Leadership Committee, Yale Cancer
Center
2012-2015
Member, Clinical Research Steering Committee, Yale Cancer Center
Hospital Boards & Committees
32
Lajos Pusztai, M.D., D.Phil
2012-present Member, Steering Committee, The Breast Center – Smilow Cancer Hospital at
Yale-New Haven
2012-present Member, Clinical Research Program Council, Smilow Cancer Hospital at YaleNew Haven
Public Service
2015
Italian Show and Festival, Discussion on Breast Center Vision and Clinical Trials,
Hartford, CT
2015
Lion Heart Walk and Fundraiser, New York, NY
Teaching / Mentoring
2007
Mentor, Mentored Dr. Michal Jarzab, ASCO IDEA Program Award
2006
Mentor, Mentored Dr. Fabrice Andre during his ASCO Career Development
Award
2005
Mentor, Mentored Dr. Stacy Moulder on her Department of Defense Career
Development Award
2004
Lecturer, GSBS Translational Research: Incorporation of genomic profile analysis
in clinical trials
2001-02
Lecturer, Translational research opportunities in breast cancer
2000-02
Lecturer, 11 lectures for medical oncology fellows, organized curriculum for
translational research seminar
Graduate Students
2015-present PhD Doctoral Student, Xiaotong Li, Yale University Computational Biology
Program New Haven, CT
2012-2016
PhD Doctoral Student, Tingting Jiang, Yale University Computational Biology
Program, New Haven, CT
2013-2015
Graduate Student, Divyansgh Agarwal, BS/MS Class 2015 Yale University, New
Haven, CT (recipient of the “Exceptional Distinction in the Major” award 2015)
2010
Research Mentor, Debora Bruno, Graduate School of Biomedical Sciences MD
Anderson Cancer Center, Houston TX
2008-12
PhD student Christine Ya-Hui Shiang, Ph.D 2012, Graduate School of
Biomedical Sciences MD Anderson Cancer Center, Houston TX
Postdoctoral Research Fellows
2012-2014
Research Mentor, Sophia Ononye, Ph.D. Postdoctoral fellow Yale University
2010
Research Mentor, Maria Pilar Sancho Marquez, MD, UT MDACC
Medical School Student MD Thesis Mentor
2014-2016
Anton Safonov, MD Class 2016, Yale University
2013-2016
Hannah Dzimitrowicz MD Class 2016, Yale University (her thesis won the
Honors Award and a prize as one of the best MD thesis of the graduating class
2016)
2013-2014
Sabrina Khan; MD Class 2014, Yale University
Clinical Residents and Fellows
33
Lajos Pusztai, M.D., D.Phil
2014-2016
2013-2014
2003-04
2002-04
2001-02
1999-2000
Research Mentor, Jaymin Patel, MD Med Onc Fellow YCC
Research Mentor, Mehmet Altan, MD, Med Onc Fellow YCC
Research Mentor, Dr. Tse-Kuan Yu, UT MDACC
Research Mentor, Dr. Jim Hou, UT MDACC
Research Mentor, Dr. Zhang Fan, UT MDACC
Research Mentor, Dr. Jorge Perez Cardona, UT MDACC
Other Supervisory Teaching
2016-2017
Research Mentor, Szekely Borbala, MD, Visiting Scientist form the National
Institute of Oncology, Budapest, Hungay (at Yale)
2016
Research Mentor, Alberto Ocana, MD, Visiting Scientist from Spain (at Yale)
2015-2016
Research Mentor, Marie Kristine Von Whalde, MD, Visiting Scientist from
University of Munster, Munster, Germany (at Yale)
2014-2016
Research Mentor, Tomoko Kurita, MD, Visiting Scientist from Nippon Medical
School Graduate School, Tokyo, Japan (at Yale)
2012-2015
Research Mentor, Bilge Aktas, M.D. Visiting Scientist from Marmara University,
Istanbul, Turkey (at Yale)
2011−12
Research Mentor, Rene Natowicz, PhD, Visiting Scientist from University of
Paris-Est, Paris, France (at Yale)
2011−12
Research Mentor, Yann Delpech, M.D. Visiting Scientist from Institute Curie,
Paris, France (at MDACC)
2010
Research Mentor, Borbala Szekely, M.D. Visiting Scientist from Semmelweis
University School of Medicine, Budapest, Hungary (at UT MDACC
2008-09
Research Mentor, Giampaolo Bianchini, M.D., Visiting Scientist from Insitut
Tumori, Milan, Italy (at UT MDACC)
2008-11
Research Mentor, Takayuki Iwamoto, M.D. Visiting Scientist from University of
Okyama, Okyama, Japan (at UT MDACC)
2008-09
Research Mentor, Charles Coutant, MD. Visiting Scientist from Institute Curie,
Paris, France (at MDACC
2009-10
Research Mentor, Catherine Kelly, Visiting Scientist from Mather Jospital
Dublin, Ireland, MD, (at UT MDACC)
2006-08
Research Mentor, Cornelia Liedtke, MD, Visiting Scientist from University of
Munster, Germany (at UT MDACC)
2006−07
Research Mentor, Fabrice Andre, MD, Institute Gustave Roussy, Paris, France (at
UT MDACC)
2006−07
Research Mentor, Attila Tordai, MD, Visiting Scientist from National Institute of
Hematology and Blood Transfusion, Budapest, Hungary (at UT MDACC)
2005−06
Research Mentor, Chafika Mazouni, MD, Institute Curie, Paris, France (at UT
MDACC)
2003−2012 Research Mentor, Bailang Wang, MD, (at UT MDACC)
2003−05
Research Mentor, Roman Rouzier, Md, Visiting Scientist from Institute Curie,
Paris, France (at UT MDACC)
2003−04
Research Mentor, Peter Wagner MD (at UT MDACC)
Supervisory Teaching Committees:
34
Lajos Pusztai, M.D., D.Phil
Supervisory Committees
2011-12
Member, Ph.D. Advisory and Examination Committee, UT Graduate School of
Biomedical Sciences, Ana Gonzalez-Angulo, MD
2005-2010
Member, Ph.D. Advisory Committee, UT Graduate School of Biomedical
Sciences, Floyd Christopher Holsinger, MD
Examining Committees
2016-2019
PhD Thesis Committee, Yale School of Public Heath, Biostatistics, Yiming Hu,
2008
PhD Thesis External Examiner, University of Melbourne, Sherene Loi.
Bibliography
Web-of-Science H-index=59 (2016)
Peer-Reviewed Original Research:
1.
Gulyas M, Pusztai L, Rappay G, Makara GB. Pituitary corticotrophs proliferate
temporarily after adrenalectomy. Histochemistry 1991, 96(2):185-9.
2.
Pusztai L, Lewis CE, McGee JO. Epidermal growth factor, insulin-like growth factor-1
and basic fibroblast growth factor modulate the cytostatic effect of tumour necrosis
TNFα on the breast cancer cell line, T47D. Cytokine 1993, 5:169-72.
3.
Pusztai L, Lewis CE, McGee JO. Growth arrest of the breast cancer cell line, T47D, by
TNFα; cell cycle specificity and signal transduction. Br J Cancer 1993, 67:290-6.
4.
Pusztai L, Lewis CE, Lorenzen J, McGee JO. Growth factors: Regulation of normal
and neoplastic growth. Journal of Pathology 1993, l 169(2):191-201.
5.
Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE, McGee JO. Expression of
tumour necrosis factor-α and its receptors in carcinoma of the breast. Br J Cancer 1994,
70:289-92.
6.
Pusztai L, Choudhry W. Recalcitrant UTI in a patient with multiple sclerosis. Hosp
Pract (Minneap) 1996, 31(3):63-6.
7.
Bast RC, Jr., Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM,
Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and
epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and
normal tissues. Hybridoma 1998, 17(4):313-21.
8.
Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM,
Mendelsohn J, Bast RC, Jr. Cell surface density of p185(c-erbB-2) determines
susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone
and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer
Res 1998, 4(10):2545-50.
9.
Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA. Coincident renal cell
carcinoma and nonHodgkin's lymphoma: The M. D. Anderson experience and review
of the literature. J Urol 1998, 159:714-7.
10. Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide
in patients with heavily pretreated metastatic breast cancer. American Journal of
Clincial Oncology 1998, 21(5):442-6.
35
Lajos Pusztai, M.D., D.Phil
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Pusztai L, Siddik ZH, Mills GB, Bast RC, Jr. Physiologic and pathologic drug
resistance in ovarian carcinoma: A hypothesis based on a clonal progression model.
Acta Oncol 1998, 37:629-40.
Pusztai L Ignaczak S. Testicular cancer presenting as acute retroperitoneal bleeding.
Hospital Physician 1998, 34:47-50.
Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN. Phase II study of mitoxantrone by
14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support
in patients with metastatic breast cancer and limited prior therapy. Cancer
Chemotherapy Pharmacology 1999, 43(1):86-91.
Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Relapse after complete response to
anthracycline-based combination chemotherapy in metastatic breast cancer. Breast
Cancer Research and Treatment 1999, 55(1):1-8.
Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald
M, DeSombre KA, Bast RC, Jr. Relative cytotoxic activity of immunotoxins reactive
with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene
product p185. Int J Cancer 1999, 82(4):525-31.
Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese
JL. Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and
pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid
tumors. Clin Cancer Res 2000, 6(4):1293-301.
Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN.
Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond.
Oncologist 2001, 6:133-46.
Sneige N, Kemp B, Pusztai L, Asmar L, Hortobagyi GN. Chemotherapy-induced
histologic changes in mastectomy specimens and their potential significance. Breast
2001, 10(6):492-500.
Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L,
Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and p38 in
primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res
2001, 7(3):171-7.
Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD,
Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of
outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer
J 2001,7(5):413-20.
Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI,
Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant
chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001,
182(6):601-8.
Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF,
Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression
changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002,
8(6):461-8.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M,
Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study
of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing
metastatic breast cancer. J Clin Oncol 2002, 20(7):1800-8.
36
Lajos Pusztai, M.D., D.Phil
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi
GN, Pusztai L. Breast cancer biomarkers and molecular medicine. Expert Rev Mol
Diagn 2003, 3(3):573-85.
Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker
SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapyinduced apoptosis and Bcl-2 levels correlate with breast cancer response to
chemotherapy. Cancer J 2003, 9(1):33-41.
Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays
in oncology. Oncologist 2003, 8(3):252-8.
Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM,
Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2
expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin,
and cyclophosphamide in patients with breast carcinoma. Cancer 2003, 97(7):1758-65
Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct
patterns of breast cancer relapse. Breast Cancer Research and Treatment 2003,
78(1):105-18.
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N,
Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V,
Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fineneedle aspirations of breast cancer reliably identify routine prognostic markers and
reveal large-scale molecular differences between estrogen-negative and estrogenpositive tumors. Clin Cancer Res 2003, 9(7):2406-15.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF,
Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal of
Clinical Pathology 2003, 120:S53-71.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ,
Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1
expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin
Cancer Res 2003, 9(15):5652-9.
Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu
ET, Hortobagyi GN. Molecular profiles of invasive mucinous and ductal carcinomas of
the breast: A molecular case study. Cancer Genet Cytogenet 2003, 141:148-53.
Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs
A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi
GN. Phase I and II study of exisulind in combination with capecitabine in patients with
metastatic breast cancer. J Clin Oncol 2003, 21(18):3454-61.
Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, 3rd,
Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in
combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol
2003, 21(17):3249-54.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L,
Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target
of therapy. Oncologist 2003, 8(4):307-25.
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA,
Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES,
Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and
37
Lajos Pusztai, M.D., D.Phil
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
microarray gene expression profiles from fine-needle aspiration biopsy and core-needle
biopsy samples of breast carcinoma. Cancer 2003, 97(12):2960-71.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi
GN, Pusztai L. Breast cancer biomarkers and molecular medicine: Part II. Expert Rev
Mol Diagn 2004, 4:169-88.
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, GalGombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN,
Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant
chemotherapy as a variable in the pathologic assessment of response. Cancer 2004,
100(7):1365-73.
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A,
Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M,
Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in
response to paclitaxel chemotherapy. Cytokine 2004, 25(3):94-102.
Pusztai L, Krishnamurthy S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M,
Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Jr, Hortobagyi
GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant
chemotherapy of locally advanced breast cancer. Cancer Invest 2004, 22(2):248-56.
Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, MericBernstam F, Marcelo Aldaz C, Hortobagyi GN, Pusztai L. Expression of sigma 1
receptor in human breast cancer. Breast Cancer Research Treatment 2004, 87(3):20514.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier
J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N,
Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic
response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and
cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22(12):2284-93.
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH,
Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin
AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for
patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and
radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59(5):1337-42.
Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L,
Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of
HER-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer
2004, 101(2):258-63.
Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L,
Hortobagyi GN. Pharmacogenomics. Adv Anat Pathol 2004, 11(4):211-20.
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ,
Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Jr,
Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and
postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant
chemotherapy for breast carcinoma. Cancer 2004, 100(9):1814-22.
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar
AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated p38
38
Lajos Pusztai, M.D., D.Phil
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast
carcinoma. Cancer 2004, 100:499-506.
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE,
Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer
2004. Am J Clin Pathol 2004, 122(4):598-609.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L,
Hortobagyi GN. Targeted therapy in breast cancer: The HER-2/neu gene and protein.
Mol Cell Proteomics 2004, 3:379-98.
Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J,
Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B,
Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker
identifies breast cancers associated with immature cell type and short duration of prior
breastfeeding. Endocr Relat Cancer 2005, 12(4):1059-69.
Whitman GJ, Iyer RB, Reeve CJ, Patel PR, Phelps MJ, Pusztai L. Assessment of
response to neoadjuvant chemotherapy in breast cancer: Imaging considerations. Semin
Breast Dis 2005, 7:61-74.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. Adv
Clin Chem 2005, 40:99-125.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess
KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN,
Pusztai L. Breast cancer molecular subtypes respond differently to preoperative
chemotherapy. Clin Cancer Res 2005, 11(16):5678-85.
Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell
S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the
predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and
Affymetrix GeneChips. J Mol Diagn 2005, 7(3):357-67.
Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M,
Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression
correlates with poor survival in patients who have breast carcinoma treated with
doxorubicin-based neoadjuvant chemotherapy. Cancer 2005, 104(4):676-81.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J,
Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi
GN, Pusztai L, Shak S. Gene expression profiles in paraffin-embedded core biopsy
tissue predict response to chemotherapy in women with locally advanced breast cancer.
J Clin Oncol 2005, 23(29):7265-77.
Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated
protein (MAP)-tau: A novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell
Cycle 2005, 4:1149-52.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P,
Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L.
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer.
Proc Natl Acad Sci U S A 2005, 102(23):8315-20.
Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar
AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D,
Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete
39
Lajos Pusztai, M.D., D.Phil
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
response and metastasis-free survival after preoperative chemotherapy for breast
cancer. J Clin Oncol 2005, 23(33):8331-9.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical
biomarkers in drug discovery and development. Am J Clin Pathol 2005, 124(Suppl
1):S29-41..
Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW,
Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase
II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with
chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104(4):682-91.
Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L,
Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple
aspirate fluid protein expression between healthy women and those with breast cancer
demonstrated by time-of-flight mass spectrometry. Breast Cancer Research and
Treatment 2005, 89(2):149-57.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L,
Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK,
Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with
trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in
human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol
2005, 23(16):3676-85.
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM,
Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear
transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response
to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer
Res 2005, 11(23):8398-402.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M,
Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans
WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves
pathologic complete remission in operable breast cancer when compared with
paclitaxel once every 3 weeks. J Clin Oncol 2005, 23(25):5983-92.
Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S,
Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib
(VELCADE) in metastatic breast cancer: Pharmacodynamics, biological effects, and
prediction of clinical benefits. Ann Oncol 2006, 17(5):813-7.
Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D,
Kuerer HM. Development and validation of nomograms for predicting residual tumor
size and the probability of successful conservative surgery with neoadjuvant
chemotherapy for breast cancer. Cancer 2006, 107(7):1459-1466.
Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for
patient selection for adjuvant chemotherapy. Pharm Res 2006, 23:1951-8.
Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L,
Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast
carcinoma recurrence and contralateral breast carcinoma development in patients with
40
Lajos Pusztai, M.D., D.Phil
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2006,
106(1):42-50.
Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV,
Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of
preoperative versus postoperative chemotherapy on the extent and number of surgical
procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg
2006, 244(3):464-70.
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D,
Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T,
Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to
preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and
cyclophosphamide in breast cancer. J Clin Oncol 2006, 24:4236-44.
Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J.
RefSeq refinements of UniGene-based gene matching improve the correlation of
expression measurements between two microarray platforms. Appl Bioinformatics
2006, 5(2):89-98.
Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y,
Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression
signature-based predictions in replicate experiments. Clin Cancer Res 2006,
12(6):1721-7.
Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU,
Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to
preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil,
epiribucin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast
Cancer Res 2007, 9(6):R87.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V,
Booser D, Pippen JE, Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N,
Hortobagyi GN, Pusztai L, Symmans WF. Determination of estrogen-receptor status
and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet
Oncol 2007, 8:203-11.
Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson
K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of
taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves
pathologic complete response rate in estrogen receptor-positive breast cancers. Ann
Oncol 2007, 18(5):874-880.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar
AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with
HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer
2007, 109:496-501..
Pusztai L. Markers predicting clinical benefit in breast cancer from microtubuletargeting agents. Ann Oncol 2007, 18(12):xii15-20..
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer HM, Valero V, Assad L,
Poniecka A, Hennessy TJ, Green MC, Buzdar AU, Singletary SE, Hortobagyi GN,
Pusztai L. Measurement of residual breast cancer burden to predict survival after
neoadjuvant chemotherapy. J Clin Oncol 2007, 25(28):4414-22.
41
Lajos Pusztai, M.D., D.Phil
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi
GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional
predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorpositive breast cancer. Clin Cancer Res 2007, 13(7):2061-2067.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L,
Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS,
Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent
trastuzumab in human epidermal growth factor receptor 2-positive operable breast
cancer: An update of the initial randomized study population and data of additional
patients treated with the same regimen. Clin Cancer Res 2007, 13(1):228-33.
Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II
clinical trials for breast cancer. Clin Cancer Res 2007, 13(20):6080-86.
Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive
lobular carcinoma of the breast. Lancet Oncol 2007, 8(1):55-62.
Mazouni C, Peintinger F, Kau SW, Andre F, Gonzalez-Angulo AM, Symmans WF,
Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual ductal carcinoma in
situ in patients with complete eradication of invasive breast cancer after neoadjuvant
chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007,
25(19):2650-2655.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in
breast cancer: Hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res
2007, 13(10):2831-2835.
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Lin F, Hortobagyi GN, Symmans
WF, Pusztai L. Thirty-gene pharmacogenomic test correlates with residual cancer
burden after preoperative chemotherapy breast cancer. Clin Cancer Res 2007,
13(14):4078-82.
Stemke-Haloe K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M,
Carey M, Hu Zhi, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H,
Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB,
Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and
AKT mutations in breast cancer. Cancer Res 2008, 68(15):6084-6091.
Mazouni C, Arun B, Andre F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN,
Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with
primary breast cancer compared to healthy volunteers. Br J Cancer 99(1):68-71, 2008.
Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist 2008,
13:350-360.
Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of
molecular disease subsets on disease-free survival in randomized adjuvant
chemotherapy trials for estrogen-receptor positive breast cancer. J Clin Oncol 2008,
26(28):4679-4683.
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi
GN, Pusztai L. Estrogen receptor expression and efficacy of docetaxel-containing
adjuvant chemotherapy in patients with node-positive breast cancer: Results from a
pooled analysis. J Clin Oncol 2008, 26(16):2636-2643.
42
Lajos Pusztai, M.D., D.Phil
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans
FW, Pusztai L. Evaluation of biological pathways involved in chemotherapy response
in breast cancer. Breast Cancer Res 2008, 10(2):R37.
Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LXH, Meslin F, Spielman M,
Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression
patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann
Oncol 2008, 19(2):315-20.
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM,
Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of
preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat
2008, 108(2):183-90.
Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM,
Pusztai L, Esteva FJ, Dawood S, Green MC, Hortobagyi GN, Symmans WF. Hormone
receptor status and pathologic response of HER2-positive breast cancer treated with
neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008, 19(12):2020-5.
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser
DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN.
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFRbeta: Clinical activity and biological correlations. Ann Oncol 2008, 19(10):1713-1719.
Wilson NM, Espirito JL, Valero V, Pusztai L. Paclitaxel-induced sickle cell crisis. Am
J Health Syst Pharm 2008, 65(14):1333-1336.
Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figueroa LJ, Hubbard RE, Valero
V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA
activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast
Cancer Res 2008, 10(2):R27.
Natowicz R, Incitti R, Horta EG, Charles B, Guinot P, Yan K, Coutant C, Andre F,
Pusztai L, Rouzier R. Prediction of the outcome of preoperative chemotherapy in
breast cancer by using DNA probes that provide information on both complete and
incomplete responses. BMC Bioinformatics 2008, 9:149.
Wollf AC, Berry D Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D,
Paik S, Pusztai L, Smith ML, Zujewski JA. Research issues affecting preoperative
systemic therapy for operable breast cancer. J Clin Oncol 2008, 26(5):806-813.
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual
specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 2008,
95(4):433-437.
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF,
Gonzalez-Angulo AM, Hennessy B, Green M, Hortobagyi GN, Pusztai L. Response to
neoadjuvant therapy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol 2008, 26(8):1275-1281.
Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M,
Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels
S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant
recurrence. The Oncologist 2009, 14(12):1182-1188.
Rouzier R, Coutant C, Lesieur B, Mazouni C, Incitti R, Natowicz R, Pusztai L. Direct
comparison of logistic regression and recursive partitioning to predict chemotherapy
43
Lajos Pusztai, M.D., D.Phil
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
response of breast cancer based on clinical pathological variables. Breast Cancer Res
Treat 2009, 117(2):325-331.
Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F,
Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of microtubule-associated
protein-tau expression as a prognostic and predictive marker in NSABP-B 28
randomized clinical trial. J Clin Oncol 2009, 27(26):4287-4292.
Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H,
Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic grade index is
associated with response to chemotherapy in patients with breast cancer. J Clin Oncol
2009, 27(19):3185-3191.
Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans
WF, Wu Y, Arlinghaus RB. Inhibition of Lipocalin 2 impairs breast tumorigenesis and
metastasis. Cancer Res 2009, 69(22):8579-8584.
Tordai A, Liedtke C, Pusztai L. Metastatic gene signatures and emerging novel
prognostic tests in the managment of early stage breast cancer. Clin Exp Metastasis
2009, 26(7):625-632.
Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B,
Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular
characterization of breast cancer with high-resolution oligonucleotide comparative
genomic hybridization array. Clin Cancer Res 2009, 15(2):441-451.
Liedtke C, Gonzalez-Angulo AM, Pusztai L, Hortobagyi GN, Kau SW, Hsu L,
Symmans WF, Woodward W, Albarracin C, Kiesel L. Prognostic impact of
discordance between triple receptor measurements in primary and recurrent breast
cancer. Ann Oncol 2009, 20(12):1953-1958.
Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C,
Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufman M. T-cell metagene predicts
a favorable prognosis in estrogen receptor negative and HER2 positive breast cancers.
Breast Cancer Res 2009, 11(2):R15.
Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: A
criterion for discovering and ranking bimodal signatures from cancer gene expression
profiling data. Cancer Inform 2009, 7:199-216.
Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Symmans WF, Hortobagyi GN, Andre F,
Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the
effects of brivanib alaninate. Breast Cancer Res Treat 2010, 123(3):747-755.
Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V,
Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C,
Pusztai L, Swanton C. Assessment of an RNA interference screen-derived mitotic and
ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for
primary triple-negative breast cancer: A retrospective analysis of five clinical trials.
Lancet Oncol 2010, 11(4):358-365.
Broom BM, Rinsurongkawong W, Pusztai L. Building networks with microarray data.
Methods Mol Biol 2010, 620:315-343.
Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K,
Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response
predictors developed from breast cancer cell lines. Breast Cancer Res Treat 2010,
121(2):301-309.
44
Lajos Pusztai, M.D., D.Phil
117. Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espie M,
Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de
The H. Cyclophosphamide dose intensification may circumvent anthracycline
resistance of p53 mutant breast cancers. The Oncologist 2010, 15(3):246-252.
118. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN,
Symmans W, Pusztai L. Development of candidate genomic markers to select breast
cancer patients for dasatinib therapy. Mol Cancer Ther 2010, 9(5):1120-1127.
119. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y,
Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M,
Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Effect of training sample size and
classification difficulty on the accuracy of genomic predictors. Breast Cancer Res
2010, 12(1):R5 doi:10.1186/bcr2468.
120. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance
between primary breast cancer and metastasis. Oncologist 2010, 15(11):1164-1168.
121. Andre F, Broglio K, Pusztai L, Berrada N, Mackey JR, Nabholtz JM, Chan S,
Hortobagyi GN. Estrogen receptor expression and docetaxel efficacy in patients with
metastatic breast cancer: A pooled analysis of four randomized trials. Oncologist 2010,
15(5):476-483.
122. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Gong Y,
Hortobagyi GN, Hess K, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel,
fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a
multicenter randomized trial in breast cancer. Cancer Res 2010, 16(21):5351-5361.
123. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, Buzdar AU, Martin PM,
Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during
neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDITOF/MS procedure. Proteomics 2010, 10(19):3525-3532.
124. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler
G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ,
Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for
breast cancer. J Clin Oncol 2010, 28(27):4111-4119.
125. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN,
Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration:
Association with triple-negative phenotype of breast cancer. Cancer 2010,
116(21):4933-4943.
126. Bianchini G, Qi Y, Hugo AR, Iwamoto T, Coutant C, Ibrahim N, Valero VV,
Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L,
Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its
prognostic value in ER-positive and -negative cancers. J Clin Oncol 2010, 28(28):43164323.
127. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan
S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to
predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin
Oncol 2010, 28(12):2032-2037.
128. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, GonzalezAngulo AM, Pusztai L, Symmans WF, Bardelli A, ellis P, Tutt ANJ, Gillett CE,
Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou
45
Lajos Pusztai, M.D., D.Phil
129.
130.
131.
132.
133.
C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and
better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA
2010, 107(22):10208-10213.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer
HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor
progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010,
28(11):1821-1828.
Bianchini G, Iwamoto T, Coutant C, Shiang C, Wang B, Santarpia L, Valero V,
Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and therapeutic
implications of distinct kinase expression patterns in different subtypes of breast
cancer. Cancer Res 2010, 70(21):8852-8862.
Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K,
Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate
predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res
2010, 16(2):711-718.
MAQC Consortium, Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ,
Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD JR, Oberthuer A, Thomas
RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas
BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B,
Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Cheng J, Chou J, Davison TS,
Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J,
Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson
R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer
EK, Luo J, Luo w, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R,
Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D,
Thierry-Mieg J, Thomida V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q,
Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas
AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui
J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, FulmerSmentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J,
Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G,
Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z,
Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA,
Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP,
Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S,
Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S,
Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY,
Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von
Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M,
Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri
RK, Scherf U. The MicroArray Quality Control (MAQC)-II study of common practices
for the development and validation of microarray-based predictive models. Nat
Biotechnol 2010, 28(8):827-838.
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach
C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M. A clinically
46
Lajos Pusztai, M.D., D.Phil
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer
Res 2011, 13(5):R97.
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes
F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon I, FerrerLozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT,
Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN,
Symmans WF. A genomic predictor of response and survival following taxaneanthracycline chemotherapy for invasive breast cancer. JAMA 2011, 305(18):18731881.
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R,
Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer
patients. Breast Cancer Res Treat 2011, 129(2):451-458.
Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes
DF, Pusztai L. Biomarker studies: A call for a comprehensive biomarker study
registry. Nat Rev Clin Oncol 23011, 8(3):171-176.
Kelly CM, Pritchard M, Trudeau E, Andreopoulou E, Hess K, Pusztai L. Coping with
uncertainty: T1a, bNOMO HER2-positive breast cancer, do we have a treatment
threshold. Ann Oncol 2011, 22:2387-2393.
Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM,
Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F,
Symmans WF, Pusztai L, Ueno NT. Different gene expression are associated with the
different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat
2011, 125(3):785-795.
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi
GN, Symmans F, Uzan S, Andre F, de The H, Pusztai L. Distinct p53 gene signatures
are needed to predict prognosis and response to chemotherapy in ER-positive and ERnegative breast cancers. Clin Cancer Res 2011 17(8):2591-2601.
Morrow PK, Serna R, Broglio KR, Pusztai L, Nikoloff DM, Hillman GR, Fontecha
MR, Li R, Michaud LB, Hortobagyi GN, Gonzalez-Angulo AM. Effect of CYP2D6
polymorphisms on breast cancer recurrence. Cancer 2011, :doi: 10.1002/cncr.26407.
Hatzis C, Sun H, Yao H, Hubbard R, Meric-Bernstam F, Babiera G, Wu Y, Pusztai L,
Symmans WF. Effects of tissue handling on RNA integrity and microarray
measurements from resected breast cancers. J Natl Cancer Inst 2011, 103(24):18711883.
Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S,
Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence
for biological effects of metformin in operable breast cancer: A pre-operative, windowof-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128(3):783-794.
Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, Kim SB,
Symmans WF, Hortobagyi GN, Pusztai L. First generation prognostic gene signatures
for breast cancer predict both survival and chemotherapy sensitivity and identify
overlapping patient populations. Breast Cancer Res Treat 2011, 130(1):155-164.
Gonzalez-Angulo AM, Hennessy BY, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey
MS, Myhre S, Speers C, Lei D, Broaddus R, Lluch AM, Aparicio S, Brown P, Pusztai
L, Symmans F, Alsner j, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coomes
47
Lajos Pusztai, M.D., D.Phil
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
KR, Mills GB. Functional proteomics can define prognosis and predict pathologic
complete response in patients with breast cancer. Clin Proteomics 2011, 8(1):11.
Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang C, Santarpia L, Matsuoka
J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen
J, Andre F, Simon R, Pusztai L. Gene pathways associated with prognosis and
chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst
2011, 103(3):264-272.
Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Mueller V,
Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhaeberle E, Kaufmann M,
Rody A. Homogeneous datasets of triple negative breast cancers enable the
identification of novel prognostic and predictive signatures. PLoS One 2011
6(12):e28403.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA,
Hortobagyi GN, Meric-Bernstam F. Impact of progression during neoadjuvant
chemotherapy on surgical management of breast cancer. Ann Surg Oncol 2011,
18(4):932-938.
Karn T, Pusztai L, Ruckhaeberle E, Liedtke C, Mueller V, Schmidt M, Metzler D,
Wang J, Coombes KR, Gaetje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A,
Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a
subset of triple negative breast cancers as candidates for immune response
augmentation. Eur J 2011, Cancer 48(1):12-23.
Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J,
Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G,
Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S,
Buyse M, Nogaret JM, Qi Y, Symmans WF, Pusztai L, D'Hondt V, Piccart-Gebhart M,
Sotiriou C. Multi-factorial approach to predicting resistance to anthracyclines. J Clin
Oncol 2011, 29(12):1578-1586.
Loi S, Symmans WF, Bartlett JMS, Fumagalli D, Van't Veer L, Forbes JF, Bedard P,
Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones R. Proposals
for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials:
Timing and specimen types. Lancet Oncol 2011, 12(12):1162-1168.
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli
M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier
R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L.
Recommendations from an International Consensus Conference on the current status
and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol.
2012, 19:1508–1516.
Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK,
Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant
systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A
single-institution experience. J Clin Oncol 2011, 29:3739-3746.
Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in
breast carcinoma: A comparison between primary and metastatic tumors with regard to
disease course and intervening systemic therapy. Cancer 2011, 117(4):705-713.
Kaufmann M, Pusztai L, Cardoso F, Dietel M, Edler L, Hahn M, Jonat W, Karn T,
Kreipe H, Loi S, von Minckwitz G, Rody A, Sinn HP, Van de Vijver M. Use of
48
Lajos Pusztai, M.D., D.Phil
155.
156.
157.
158.
159.
160.
161.
162.
163.
standard markers and incorporation of molecular markers into breast cancer therapy:
Consensus recommendations from an International Expert Panel. Cancer 2011,
117(8):1575-1582.
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM,
Hortobagyi GN, Pusztai L. Utility of Oncotype DX risk estimates in clinically
intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph nodenegative breast cancers. Cancer 2011, 116(22):5161-5167.
Berruti A, Generali D, Kaufmann M, Pusztai L, Curigliano G, Aglietta M, Gianni L,
Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini
P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C,
Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M,
Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van’t Veer L, Harris
AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic
therapy in the management of early breast cancer: Highlights of the Fourth Symposium
on primary systemic therapy in the management of operable breast cancer. J Natl
Cancer Inst Monogr 2011, 2011(43):147-151.
Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF,
Pusztai L, Brunak S, Richardson AL, Szallasi Z. Consistent metagenes from cancer
expression profiles yield agent specific predictors of chemotherapy response. BMC
Bioinformatics 2011, 12(1):310.
Dutta B, Pusztai L, Qi Y, Andre F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang
B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balazsi G. A network-based,
integrative study to identify core biological pathways that drive breast cancer clinical
subtypes. Br J Cancer 2012, 106(6):1107-1116.
Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently
strong informative features limits the potential of gene expression analysis as predictive
tool for many clinical classification problems. BMC Bioinformatics 2012, 12:463.
(doi:10.1186/1471-2105-12-463).
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J,
Shi W, Qi Y, Matsuoka J, Young EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai
L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that
are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012, 30(7):729734.
Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB,
Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class
changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.
Clin Cancer Res 2012, 18(4):1109-1119.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H,
Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z,
Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G,
Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A
randomized, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
Schwartz G, Reis-Filho J, Pusztai L, Fentiman I, Holland R, Bartelink H, Rutgers E,
Einstein S, Jefferson JP. Adjuvant therapy in stage I carcinoma of the breast: The
49
Lajos Pusztai, M.D., D.Phil
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
influence of multigene analyses and molecular phenotyping. Cancer 2012,
118(8):2013-2038.
Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MTW, Bastien RRL,
Boucher K, Yang CY, Iwamoto T, Pusztai L. Agreement in risk prediction between the
21-gene recurrence score assay (OncotypeDX(R) and the PAM50 breast cancer
intrinsic classifier in early stage ER-positive breast cancer. Oncologist 2012, 17(4):4928.
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R,
Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer
patients. Breast Cancer Res Treat 2012, 129(2):451-458.
Jung EJ, Santarpia L, Yeon J, Esteva FJ, Moretti E, Buzdar A, DiLeo A, Le XF, Bast
RC, Robinson R, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels
correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Cancer 2012, 118(10):2603-2614.
Chen W, Yousef WA, Gallas BD, Hsu ER, Lababidi S, Tang R, Pennello GA,
Symmans WF, Pusztai L. Uncertainty estimation with a finite dataset in the assessment
of classification models. Computational Statistics and Data Analysis 2012, 56:10161027.
Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity:
Seeing the wood for the trees. Sci Transl Med 2012, 4(127):127ps10.
Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA,
O’Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V,
Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns
in different clinical subtypes of breast cancers. Breast Cancer Research Treatment
2012, 134 (1), 333-343.
McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A,
an essential centromere protein, is a prognostic marker for relapse in estrogen receptorpositive breast cancer. Breast Cancer Research Treatment 2012, 14(3), R72.
Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, Plassa LF,
Cottu P, Marty M, Andre F, Sotiriou C, Pusztai L, Hughes de The. Distinct PT53
mutants in breast cancers subgroups. International Journal of Cancer 2012, 132(5):
1227-1231.
Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE,
Zacksenhaus E. Seventeen-gene signature from enriched HER2/Neu mammary tumorinitiating cells predicts clinical outcome for human HER2+:ER breast cancer. Proc Natl
Acad Sci USA 2012, 109(15):5832-5837.
Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R,
Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary
tumor predicts for clinical benefit and time to progression on first line endocrine
therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research
Treatment 2012, 135 (2): 619-627.
Shen K, Song N, Qi Y, Tian C, Rice SD, Gabrin M, Browner SL, Symmans WF,
O’Shaughnessy JA, Holmes FA, Asmar L, Pusztai, L. Cell Line Derived Multi-Gene
Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A
50
Lajos Pusztai, M.D., D.Phil
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
Validation Study on US Oncology 02-103 Clinical Trial. BMC Med Genomics 2012,
5(1): 51.
Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas C H, Hortobagy G N,
Rouzier R, Esteva F J, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in
oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal of
Cancer 2013, 108(2): 285-291.
Bayraktar S., Gutierrez Barrera A., Liu D., Pusztai L., Litton J., Valero V., Hunt K.,
Hortobagyi G., Wu Y., Symmans F., Arun B.. USP-11 as a Predictive and Projnostic
Factor following Neoadjuvant Therapy in Woman with Breast Cancer. Cancer Journal
2013 January : 19(1): 10-17
Torikoshi Y., Gohda K., Davis M., Fraser Symmans W., Pusztai L., Kazansky A.,
Nakayama S., Yoshida T., Matsushima T., Hortobagyi G., Ishihara H., Jin Kim S.,
Noguchi S., Ueno N.. Novel Function Assay for Spindle-Assembly check-point by
Cyclin-Depent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor
Patient. Journal of Cancer 2013 4(9): 697-702
Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted
therapeutics. British Journal of Cancer 2013 108,479-485
Hanker L., Rody A., Holtrich U., Pusztai L., Ruckhaeberle E., Liedtke C., Ahr A.,
Heinrich T., Sanger N., Becker S., Karn T.. Prognostic evalution of the B cell/IL-8
metagene in differnent intrinsic breast cancer subtypes. Breast Cancer Res. Treat. 2013
137:407-416
Masuda H., Baggerly K., Wang Y., Iwamoto T., Brewer T., Pusztai L., Kai K.,
Kogawa T., Finetti P., Birnbaum D., Dirix L., Woodward W., Reuben J.,
Krishnamurthy S., Frase Symmans W., Van Laere S., Bertucci F., Hortobagyi G., and
Ueno N.. Comparison of molecular subtype distribution in triple-negative inflammatory
and non-inflammatory breast cancers. Breast Cancer Research 2013 15:R112.
PMCID:PMC3978878
Haibe-Kains B., Desmedt C., Di Leo A., Azambuja E., Larsimont D., Selleslags J.,
Delaloge S., Duhem C., Kains J., Carly B., Maerevoet M., Vindevoghel A., Rouas G.,
Lallemand F., Durbecq V., Cardoso F., Salgado r., Rovere R., Bontempi G., Michiels
S., Buyse M., Nogaret J., Qi Y., Symmans F., Pusztai L., Hondt D., Piccart-Gebhart
M., Sotiriou C.. Genome-wide gene expression profiling to predict resistance to
anthracyclines in breast cancer patients. Genomics Data 2013, December 1: 7-10
Dumay A., Feugeas J., Wittmer E., Lehmann-Che J., Bertheau P., Espie M., Plassa L.,
Cottu P., Marty M., Andre F., Sotiriou C., Pusztai L., and de The H.. Distinct tumor
protein p53 mutants in breast cancer subgroups. 2013 International Journal of Cancer
132, 1227-1231
Wang X., Saso H., Iwamoto T., Xia W., Gong Y., Pusztai L., Woodward W.,
RebuenJ., Warner S., Bearss D., Hortobagyi G., Hung M., and Ueno N.. TIG1
Promotes the Development and Progession of Inflammatory Breast Cancer through
Activation of Axl Kinase. 2013 Cancer Research Nov 1 73(21); 6516-25
Saura C., Tseng L., Chan S., Chacko R., Campone M., Manikhas A., Nag S., Leichman
C., Dasappa L., Faschin P., de Mendoza F., Fraser Symmans W., Liu D.,
Mukhopadhyay P., Horak C., Xin G., Puszai L.. Neoadjuvant
Doxorubicin/Cyclophosphamide followed by Ixabepilone or Paclitaxel in Early Stage
51
Lajos Pusztai, M.D., D.Phil
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker. 2013
The Oncologist 18:787-794
Liedtke C, Hess K R, Karn T, Rody A, Kiesel L, Hortobagyi G N, Pusztai L, A-M
Gonzalez-Angulo. The prognostic impact of age in patients with triple negative breast
cancer. Breast Cancer Research and Treatment 2013 138 (2), 591-599.
DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE,
Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz CC, Chien AJ,
Haluska P, Leyland-Jones B, Liu MC, Munster PN, Olopade OI, Park JW, Parker BA,
Pusztai L, Tripathy D, Rugo H, Yee D, Esserman LJ. Developing safety criteria for
introducing new agents into Neoadjuvant trials. Clinical Cancer Research 2013,
19(11):2817-23.
Esteva FJ, Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL,
Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN. Elevated serum P1NP
predicts development of bone metastasis and survival in early-stage breast cancer.
Breast Cancer Research and Treatment 2013, 137(2), 631-636.
Horak C, Pusztai L, Xing G, Trifan O, Saura C, Tseng LM, Chan S, Welcher R, Liu D.
Biomarker analysis of Neoadjuvant Doxorubicin/Cyclophosphamide followed by
Ixabepilone or Paclitaxel in early-stage breast cancer. Clinical Cancer Research 2013,
19(6), 1587-1595.
Szekely B, Iwamoto T, Matsuoka J, Szasz M, Szallasi Z, Tokes AM, Kulka J, Pusztai
L. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade 2, ERpositive breast cancers into low and high risk prognostic categories. Breast Cancer
Research and Treatment 2013. 138 (3), 691-698.
Trentini F., Ji Y., Iwamoto T., Qi Y., Pusztai L., and Muller P.. Bayesian Mixture
Models for Assessment of Gene Differential Behaviour and Prediction of pCR through
the Integration of Copy Number andGene Expression Data. PLoS One 2013, 8 (7):
e68071.
Holder A., Gonzalez-Angulo A., Chen H., Akcakanat A., Ka D., Fraser Symmans W.,
Pusztai L., Hortobagyi G., Mills B., and Meric Bernstam F.. High stearoyl-CoA
desaturase 1 expression is associated with shorter survival in breast cancer patients.
Breast Cancer Research and Treatment. 2013. Jan;137(1):319-27.
Rae J., Regan M., Thibert J., Gersch C., Thomas D., Leyland-Jones B., Viale G.,
Pusztai L., Hayes D., Skaar T., and Van Poznak C.. Concordance between Cyp2D6
Genotypes Obtained From Tumor-Dervived and Germline DNA. Journal of the
National Cancer Institute 2013. Sept 4, 105 (17): 1332-1334
Pusztai L., Andre F., and Hatzis C.. Reproducibility of research and preclinical
validation: problems and solutions. Nature Reviews Clincial Oncology 2013.
Dec;10(12):720-4
Frampton A., Fichtenholtz A., Otto G., Wang K., Downing S., He J., Schnall-Levin M.,
White J., Sanford E., An P., Sun J., Brennan K., Juhn F., Brennan K., Iwanik K.,
Maillet A., Buell J., White E., Zhao M., Balasubramanian S., Terzic S., Richards T.,
Banning V., Garcia L., Mahoney K., Zwirko Z., Donahue A., Beltran H., Mosquera J.,
Rubin M., Dogan S., Hedvat C., Berger M., Pusztai L., Lechner M., Boshoff C., Jarosz
M., Vietz C., Parker A., Miller V., Ross J., Curran J., Cronin M., Stephens P., Lipson
D. and Yelensky R.. Development and validation of a clinical cancer genomic profiling
52
Lajos Pusztai, M.D., D.Phil
195.
196.
197.
198.
199.
200.
201.
202.
203.
test based on massively parallel DNA sequencing. Nature Biotechnology 2013. Nov;
31 (11):1023-31
Santarpia L., Iwamoto T., Di Leo A., Hayashi I., Bottai G., Stampfer M., Andre F.,
Turner N., Wymmans W., Hortobagyi G., Pusztai L., and Bianchini G.. DNA Repair
Gene Patterns as Prognostic and Predicitive Factors in Molecular Breast Cancer
Subtypes. The Oncologist 2013. 2013;18(10):1063-73. PMCID:PMC3805146
Bianchini G., Pusztai L., Karn T., Iwamoto T., Rody A., Kelly c., Muller V., Schmidt
M., Qi Y., Holtrich U., Becker S., Santarpia L., Fasolo A., Del Conte G., Zambetti M.,
Sotiriou C., Haibe-Kains B., Symmans W., and Gianni L.. Proliferation and estrogen
signaling can distinguish patients at risk for early versus late relapse amoung estrogen
receptor positive breast cancers. Breast Cancer Research 2013. Sep 23;15(5):R86
Masuda H., Baggerly K., Wang Y., Iwamoto T., Brewer T., Pusztai L., Kai K., Finetti
P., Birnbaum D., Dirix L., Woodward W., Reuben J., Krishnamurthy S., Symmans F.,
Van Laere S., Bertucci F., Hortobagyi G., Ueno N., and Kogawa T.. Comparison of
Molecular Subtype Distribution in Triple-Negative Inflammatory and Noninflammatory Breast Cancers. Breast Cancer Research 2013. Nov 25;15(6):R112
Fenn K., Evans S., McCorkle R., DiGiovanna M., Pusztai L., Sandt T., Hofstatter E.,
Killelea B., Knobf T., Lannin D., Abu-Khalaf M., Horowitz N., Chagpar A.. Impact of
Financial Burden of Cancer on Survivors’ Quality of Life? Journal of Oncology
Practice 2013 May 27. pii: 001322
Itoh M., Iwamoto T., Matsuoka J., Nogami T., Motoki T., Shein T., Taira N., Niikua
N., Hayashi N., Ohtani S., Higaki K., Fujiwara T., Doihara H., Fraser Symmans W.,
Pusztai L.. Estrogen receptor (ER) mRNA expression and molecula subype
distribution in ER-Negative/Progesterone receptor-positive breast cancers. Breast
Cancer Res Treat 2014 143:403-409
Kai K., Iwamoto T., Kobayashi T., Arima Y., Takamoo Y., Ohnishi N., Bartholomeusz
C., Horii R., Akiyama F., Hortobagy G., Pusztai L., Saya H., Ueno N.. Ink4a/Arf -/and HRAS(G12V) tansform mouse mammary cells into intriple-negative breast cancer
containing tumorigenic CD49f – quiescent cells. Oncogene 2014 33, 440-448
Jeselsohn R., Yelensky R., Buchwaler G., Frampton G., Meric-Bernstam F., GonzalezAngulo A., Ferer-Lozano J., Perez-Fidalgo A., Cristofanilli M., Gomez H., Arteaga C.,
Giltnane J., Balko J., Cronin M., Jarosz M., Sun J., Hawryluk M., Lipson D., Otto G.,
Ross J., Dvir A., Soussan-Gutman L., Wolf I., Rubinek T., Gilmore L., Schnitt S.,
Come S., Pusztai L., Stephens P., Brown M., Miller V.. Emergence of constitutively
active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive
breast cancer. Clincal Cancer Research 2014 Apr 1;20(7):1757-67.
Gyorffy B., Bottai G., Lehmann-Che J., Keri G., Orfi L., Iwamoto T., Desmedt C.,
Bianchini G., Turner N., de The H., Andre F., Sotiriou C., Hortobagi G., Di Leo A.,
Pusztai L., Santarpia L.. TP53 mutation-correlated genes predict the risk of tumor
relapse and identify MSP1 as a potential therapeutic kinase in TP53-mutated breast
cancers. Molecular Oncology 2014 May Volume 8, Issue 3:508-519.
Aktas B., Sun Hongxia, Yao H., Shi W., Hubbard R., Zhang Y., Jiang T., Ononye S.,
Wali V., Pusztai L., Symmans W., and Hatzis C.. Global Gene Expression Changes
Induced By Prolonged Cold Ischemic Stress and Preservation Method of Breast Cancer
Tissue. Molecular Oncology 2014. May;8(3):717-27. PMCID:PMC4048748
53
Lajos Pusztai, M.D., D.Phil
204. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL,
Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompsom S, Litton JK,
Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A,
Giordano SH, Pusztai L, Do K-A, Mills GB, Hortobagyi GN, Meric-Bernstam F..
Open label randomized clinical trial of standard neoadjuvant chemotherapy with
paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed
by FEC in women with triple receptor-negative breast cancer. Annals of Oncology 2014
Jun;25(6):1122-7. PMCID:PMC4037860
205. Shi W., Balazs B., Gyorffy B., Jiang T., Fraser Symmans W., Hatzis C., Pusztai L..
Combined analysis of gene expression, DNA copy number, and mutation profiling data
to display biological process anomalies in individual breast cancers. Breast Cancer
Res. Treat 2014 144:561-568
206. Schalper K., Velcheti V., Carvajal D., Winberly H., Brown J., Pusztai L., Rimm D.. In
Situ Tumor PD-L1 mRNA expression is associated with increased TILs and better
outcome in breast carcinomas. Clincial Cancer Research 2014 May 15;20(10):277382.
207. Fuentes-Mattei E., Velazquez-Torres G., Phan L., Zhang F., Chou P., Shin J., Choi H.,
Chen J., Zhao R., Chen J., Gully C., Carlock C., Qi Y., Zhang Y., Wu Y., Esteva F.,
Luo Y., McKeehan W., Ensor J., Hortobagy G., Pusztai L., Fraser Symmans W., Lee
M., Jim Yeung S.. Effects of Obesity on Transcriptomic Changes and Cancer
Hallmarks in Estrogen Receptor-Positive Breast Cancer. Journal of the National
Cancer Institute 2014 Jun 23;106(7). PMCID:PMC4110474
208. Chavez-MacGregor M., Liu S., Melo-Gagliato D., Chen H., Do H., Pusztai L.,
Symmans W., Nair L., Hortobagyi G., Mills G., Meric-Bernstam F., Gonzlez-Angulo
A.. Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on
Breast Subtypes. Cancer Epidemiology, Biomarkers and Prevention 2014
Feb;23(2):316-23.
209. Vasan N., Yelensky R., Wang K., Moulder S., Dzimitrowicz H., Avritscher R., Wang
B., Wu Y., Cronin M., Palmer G., Fraser Symmans W., Miller V., Stephens P., Pusztai
L.. Targeted Next-Generation Sequencing Assay Detects a High Frequency of
Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers:
Implications for Clinical Practice. The Oncologist 19:1-6, 2014. PMCID: PMC4012963
210. Pelicano H., Zhang W., Liu J., Hammoudi N., Dai J., Xu R., Pusztai L., Huang P..
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of
mTOR pathway and therapeutic potential. Breast Cancer Research 2014, 16:434.
PMCID:4303115
211. Jiang T., Shi W., Natowicz R., Ononye S., Wali V., Kluger Y., Pusztai L. Hatzis C..
Statistical measures of transcriptional diversity capture genomic heterogeneity of
cancer. BMC Genomics 2014, 15:876. PMCID:PMC4197225
212. Ononye S., Shi W., Wali B., Aktas B., Jiang T., Hatzis C., Pusztai L.. Metabolic
isoenzyme shifts in cancer as potential novel therapeutics targets. Breast Cancer
Research and Treatment, 2014, Volume 148(3):477-488
213. Pusztai, L., Moulder S., Altan Mehmet., Dwiatkowski D., Valero V.., Ueno N., Esteva
F., Avritscher R., Qi Y., Strauss L., Hortobagyi G., Hatzis C., Fraser Symmans W..
Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical
Cancer Research 2014 , 20(20):5265-71 .
54
Lajos Pusztai, M.D., D.Phil
214. Karn T., Rody A., Muller V., Schmidt M., Becker S., Holtrich U., and Pusztai L.
Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer,
Genomics Data 2014, 2:354-356
215. Sistigu A., Yamazaki T., Vacchelli e., Chaba K., Enot d., Adam J., Vitale I., Goubar A.,
Baracco E., Remedious C., Fend L., Hannani D., Aymeric L., Ma Y., Niso-Santano M.,
Kepp O., Schultze J., Tuting T., Belardelli F.,. Bracci L., La Sorsa V., Ziccheddu G.,
Sestili P., Urbani F., Delorenzi M., Lacrioux-Triki M., Quidville V., conforti R., Spano
J., Pusztai L.,Poirier-Colame V., Delaloge S., Penault-Llorca F., Ladiore S., Arnould
L., Cyrta J., Dessoliers M., Eggermont A., Bianchi M., Pittet M., Engblom C.,
Pfirschke C., Preville X., Uze G., Schreiber R., Chow M., Smyth M., Proietti E., Andre
F., Kroemer G., Zitvogel L.. Cancer cell-autonomous contribution of type I interferon
signaling to the efficacy of chemotherapy. Nature Medicine 2014, 20 (11):1301-9
216. Wimberly H., Brown J., Schalper K., Haack H., Silver M., Nixon C., Bossuyt V.,
Pusztai L., Lannin D., Rimm D.. PD-L1 expession correlates with tumor-infiltrating
lumphocytes and response to meoadjuvant chemotherapy in breast cancer. Cancer
Immunology Research , 2015, 3(4):326-332. PMCID:PMC4390454
217. Gyorffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic
tests in breast cancer: past, present, future. Breast Cancer Res 2015;17:11.
218. Thaker N., Hoffman K., Stauder M., shaitelman S., Strom E., Tereffe W., Smith B.,
Perkins G., Huo L., Munsell M., Pusztai L., Buchholz T., and Woodward W. the 21gene recurrence score complements IBTR! Estimates in early-stage, hormone receptorpositive, HER2-normal, lymph node-negative breast cancer. Springerplus 2015, 4:36.
PMCID:PMC4318826
219. Kahn S., Karn T., Symmans W., Rody A., Muller V., Holtrich U., Becker S., Pusztai
L., Hazis C. Genomic Predictor of Residual Risk of Recurrence after Adjuvant
Chemotherapy and Endocrine Therapy in High Risk Estrogen Receptor Positive Breast
Cancers. Breast Cancer Research and Treatment 2015, Volume 149, Issue 3: 789-797
220. Killelea B., Yang Y., Mougalian S., Horowitz N., Pusztai L., Chagpar A., Lannin D..
Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation:
results from the national cancer database. Journal of American College of Surgeons
2015, 220(6):1063-9.
221. Gardeux V., Chelouah R., Wanderley M., Siarry P., Braga A., Reyal F., Rouzier R.,
Pusztai L., Natowicz R.. Computing Molecular signatures as optima of a bi-objective
function: method and application to prediction in oncogenomics. Cancer Inform. 2015
Apr 19;14:33-45. PMCID:PMC4426938
222. Bulloch K., Irwin M., Chagpar A., Pusztai L., Killelea B., Horowtiz N., Hofstatter E.,
Abu-Khalaf M., DiGiovanna M., Chung G., and Sanft T. Systematic approach to
providing breast cancer servivors with survivorship care plans: a feasibility study.
Journal of Oncology Practice 2015, 11(2):e170-6
223. Agarwal D., Hatzis C., Pusztai L. Functional polymorphisms in cancer. Oncoscience
2015, Vol 2, No. 2: 73-74. PMCID:PMC4381696
224. Carvajal-Hausdorf D., Schalper K., Pusztai L, Psyrri A, Kalogeras KT, Kotoula V,
Fountzilas G,Rimm DL. Measurement of Domain-Specific HER2 (ERBB2) Expression
May Classify Benefit From Trastuzumab in Breast Cancer. J Natl Cancer Inst. 2015
May 19;107(8). PMCID:PMC4554192
55
Lajos Pusztai, M.D., D.Phil
225. Qi, Y., Liu X., Liu, C., Wang B., Hess K., Fraser-Symmans W., Shi W., Pusztai L..
Reproducibility of Variant Calls in Replicate Next Generation Sequencing
Experiments. PlosOne 2015; 10(7):e0119230. PMCID:PMC4489803
226. Mougalian S., Soulos P., Killelea B., Lannin D., Abu-Khalaf M., DiGiovanna M., Sanft
T., Pusztai L, Gross C., Chagpar A. Use of neoadjuvant chemotherapy for patients with
stage I to III breast cancer in the United States. Cancer 2015;121(15):2544-52.
227. Gyorffy B., Karn T., Sztupinszki Z., Weltz B., Muller V., Pusztai L. Dynamic
classification using case-specific training cohorts outperforms static gene expression
signatures in breast cancer. Int. J. Cancer 2015;136(9):2091-8. PMCID:PMC4307898
228. Chagpar AB., Killelea BK., Tsangaris TN., Butler M., Stavris K., Li F., Yao X.,
Bossuyt V., Harigopal M., Lannin DR., Pusztai L., Horowitz NR. A randomized
controlled trial of cavity shave margins in breast cancer. New Eng J Med. 2015;
373(6):503-10. PMCID:PMC4354298
229. Phan L., Chou P., Velazquez-Torres G., Samudio I., Parreno K., Huang Y., Tseng C.,
Vu T., Gully C., Su C., Wang E., Chen J., Choi H., Fuentes-Mattei E., Shin J., Shiang
C., Grabiner B., Blonska M., Skerl S., Shao Y., Cody D., Delacerda J., Kingsley C.,
Webb D., Carlock C., Zhou Z., Hsieh Y., Lee J., Elliott A., Ramirez M., Bankson J.,
Hazle J., Wang Y., Li, L., Weng S., Rizk N., Wen Y., Lin X., Wang H., Wang H.,
Zhang A., Xia Y., Habra M., Yang W., Pusztai L., Yeung S., Lee M.. The cell cycle
regulator 13-3-3o opposes and reverses cancer metabolic reprogramming. Nature
Communications 2015;6:7530. PMCID:PMC4507299
230. Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M,
Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between complete
pathologic response to neoadjuvant chemotherapy and survival in triple negative breast
cancer. Clin Cancer Res. 2016, 22: 26-33 , 2015 published on-line Aug 18; PMID:
26286912)
231. Aktas B., Sorkin M., Pusztai L., Hofstatter E. Uptake of exemestane chemoprevention
in postmenopausal women at increased rick for breast cancer. Eur J Cancer Prevention
2016 Jan;25(1):3-8.
232. Bonneau C, Gurard-Levin ZA, Andre F, Pusztai L, Rouzier R: Predictive and
Prognostic Value of the TauProtein in Breast Cancer. Anticancer Res. 2015 Oct. PMID:
26408675
233. Agarwal D, Qi Y, Jiang T, Liu X, Shi W, Wali VB, Turk B, Ross JS, Fraser Symmans
W, Pusztai L, Hatzis C: Characterization of DNA variants in the human kinome in
breast cancer. Sci Rep. 2015, 5: 14736. Sep 30; 2015 Sep 30. PMID: 26420498
234. Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E,
Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK: Clinical nomogram to predict bone-only
metastasis in patients with early breast carcinoma. Br J Cancer. 2015 Sep 29; 2015 Sep
22. PMID: 26393887
235. Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch
A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL,
Semiglazov V, Valagussa P, Gianni L: Immune modulation of pathologic complete
response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol.
2015 Sep 19; 2015 Sep 19. PMID: 26387142
236. Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A,
Tarricone R: A network meta-analysis of everolimus plus exemestane versus
56
Lajos Pusztai, M.D., D.Phil
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
chemotherapy in the first- and second-line treatment of estrogen receptor-positive
metastatic breast cancer. Breast Cancer Res Treat. 2015 Jul; 2015 Jun 5. PMID:
26044370
Pongor L, Kormos M, Hatzis C, Pusztai L, Szabó A, Győrffy B: A genome-wide
approach to link genotype to clinical outcome by utilizing next generation sequencing
and gene chip data of 6,697 breast cancer patients. Genome Med. 2015 Oct 16; 2015
Oct 16. PMID: 26474971
Zheng Y, Qing T, Song Y, Zhu J, Yu Y, Shi W, Pusztai L, Shi L: Standardization
efforts enabling next-generation sequencing and microarray based biomarkers for
precision medicine. Biomark Med. 2015 Oct 26; 2015 Oct 26. PMID: 26502353
Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A,
Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L,
Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J: High
HER2 expression correlates with response to the combination of lapatinib and
trastuzumab. Clin Cancer Res. 2015 Feb 1; 2014 Dec 2. PMID: 25467182.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G,
Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L.
Prospective assessment of the decision-making impact of the Breast Cancer Index in
recommending extended adjuvant endocrine therapy for patients with early-stage ERpositive breast cancer. Breast Cancer Res Treat. 2015 154(3), 533-541
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB,
Pusztai L, Lannin DR: Racial Differences in the Use and Outcome of Neoadjuvant
Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. J Clin
Oncol. 2015 33(36): 4267-4276. PMID: 26598753 33.36
Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy
B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ: miR-34a Silences c-SRC to
Attenuate Tumor Growth in Triple Negative Breast Cancer. Cancer Res. 2016 Feb
15;76(4):927-39. PMCID: PMC4755913
Aktas B, Sorkin M, Pusztai L, Hofstatter EW: Uptake of exemestane chemoprevention
in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev. 2016
Jan. PMID: 25642790
Safonov A, Wang S, Gross CP, Agarwal D, Bianchini G, Pusztai L, Hatzis C.
Assessing Cost-Utility of Predictive Biomarkers in Oncology: A Streamlined
Approach. Breast Cancer Res Treat 2016 Jan;155(2):223-34
Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A,
Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt M, Shi W, Gershkovich P,
Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation
sequencing data: A comparison of web tools. Oncotarget, 2016 PMID 26980737
Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft
TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW:
Patient preferences regarding incidental genomic findings discovered during tumor
profiling. Cancer. 2016 Mar 11; 2016 Mar 11. PMID: 26970385
Nanda R, Chow L, Claire Dees E, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K,
Aktan G, Cheng J, Karantza V, and Buisseret L. Pembrolizumab in Patients with
Advanced Triple-Negative Breast Cancer: Phase Ib Keynote-012 Study. J Clin Oncol.
2016 May 2; PMID: 27138582
57
Lajos Pusztai, M.D., D.Phil
248. Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M,
Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L,
Davidoff AJ, Gross CP: Economic Impact of Routine Cavity Margins Versus Standard
Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled
Trial. Ann Surg. 2016 May 17; PMID: 27192352
249. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M,
Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM,
Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang
JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston
KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C,
Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2
Investigators: Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast
Cancer. N Engl J Med. 2016 Jul 7. PMID: 27406347
250. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter
J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM,
Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R,
Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder
SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M,
Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry
DA, I-SPY 2 Investigators: Adaptive Randomization of Neratinib in Early Breast
Cancer. N Engl J Med. 2016 Jul 7. PMID: 27406346
251. Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L: Deciphering and
Targeting Oncogenic Mutations and Pathways in Breast Cancer. The Oncologist. 2016
Jul 6; 2016 Jul 6. PMID: 27384237
252. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS,
Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R: T-DM1 Activity in Metastatic
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received
Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. 2016 Jun 13; 2016 Jun
13. PMID: 27298406
253. Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB,
Pusztai L, Rimm DL: Quantitative assessment of the spatial heterogeneity of tumorinfiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016 Jul 29; 2016 Jul 29.
PMID: 27473061
254. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA,
Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB,
Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to
neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide
improves pathologic complete response (pCR) rates in inflammatory or locally
advanced breast cancer. Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi:
10.1007/s10549-016-3889-6
255. von Wahlde MK, Timms KM, Chagpar AB, Wali VB, Jiang T, Bossuyt V, Saglam O,
Reid JE, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L: Intratumor
heterogeneity of homologous recombination deficiency in primary breast cancer. Clin
Cancer Res. 2016 Sep 6; 2016 Sep 6. PMID: 27601588
58
Lajos Pusztai, M.D., D.Phil
256. Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L: Deciphering and
Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist. 2016 Sep;
2016 Jul 6. PMID: 27384237
257. Sanft T, Pusztai L: Clinical Utility of Biomarker Tests in Decisions on Extended
Endocrine Therapy. J Clin Oncol. 2016 Aug 22; 2016 Aug 22. PMID: 27551119
258. Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C: Testing
violations of the exponential assumption in cancer clinical trials with survival
endpoints. Biometrics. 2016 Sep 26; 2016 Sep 26. PMID: 27669414
259. Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson
SL, Thompson AM: A prospective comparison of ER, PR, Ki67 and gene expression in
paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer. 2016
Sep 22; 2016 Sep 22. PMID: 27658825
Scholarships In Press
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S,
Hortobagyi GN, Lajos Pusztai, Symmans WF, Ueno NT. Bone metastasis-related
signaling pathways in breast cancers stratified by estrogen receptor status. J Cancer (in
press), 2016
Book Chapters
1.
Lorenzen J, Pusztai L, McGee J. Growth factors. In: Oxford Textbook of Pathology. 1.
Oxford University Press, 1992, pp. 673-680.
2.
Pusztai L, Cooper K. Cell proliferation and carcinogenesis. In: Cell Proliferation in
Cancer: Regulatory mechanisms of neoplastic cell growth. Oxford University Press, 125, 1995.
3.
Pusztai L, Symmans WF, Meric F, Clark E. Gene expression profiles from fine needle
aspirate biopsies of breast cancer. In: Computational and Statistical Approaches to
Genomics. Ed(s) W Zhang, I Shmulevich. Kluwer Academic Publishers, 2002, pp. 257276.
4.
Hortobagyi GN, Hayes D, Pusztai L. Integrating newer science into breast cancer
prognosis and treatment. In: Molecular Predictors and Profiles. In: ASCO 2002 Annual
Meeting Summaries, 2002, pp. 191-202.
5.
Pusztai L, Hess KR. Design and integration of transcriptional profiling studies into
clinical trials. In: American Society of Clinical Oncology, 2004 Education Book,
ASCO, 2004, pp. 153-158.
6.
Pusztai L, Stec J, Ayers M, Ross JS, Wagner P, Rouzier R, Symmans WF, GN
Hortobagyi GN. Pharmacogenetics, pharmacogenomics and predicting response to
therapy, Chapter 28. In: Molecular Oncology of Breast Cancer. Ed(s) JS Ross, GN
Hortobagyi. Jones & Bartlett, 2004, pp. 439-457.
7.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. In:
Advances in Clinical Chemistry Elsevier Academic Press. 40. Ed(s) GS Makowski,
2005, pp. 99-125.
59
Lajos Pusztai, M.D., D.Phil
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Pusztai L, Tanyi J, Hortobagyi GN. Current status of cytotoxic treatment of breast
cancer: What gynecological oncologists should know about chemotherapy. In:
European Academy of Gynecological Cancer. Ed(s) P Bosze, M Markman. NOK Press,
Budapest, 2006, pp. 195-205.
Pusztai L. Development of pharmacogenomic predictors for preoperative
chemotherapy of breast cancer. In: Adv Exp Med Biol. 587. Ed(s) JA Lopez-Guerrero,
A Lombart-Bosch, V Felipo. Springer Verlag, 2006, pp. 233-49.
Pusztai L. Molecular markers for treatment decision. In: Textbook of Breast Cancer: A
Clinical Guide to Therapy. Ed(s) P Valagussa. Mosby, 2006, pp. 81-101.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and
Pharmacogenetics in Prostate Cancer. In: The Molecular Oncology of Prostate Cancer.
Ed(s) JS Ross, CF Foster. Sudbury, MA Jones and Bartlett, Inc., 2006, pp. 475-485.
Ross JS, Linette GP, Stec J, Clark JE, Ayers M, Symmans WF, Hortobagyi GN,
Pusztai L. The molecular pathology of breast cancer. In: Molecular Pathology in
Clinical Practice. Springer-Verlag, 2006, pp. 263-272.
Pusztai L, Liedtke C, Tordai A. Gene expression profiling to select patients for
chemotherapy. In: American Society of Clinical Oncology, 2007 Education Book,
ASCO. 1092-9118, 2007, pp. 64-66.
Symmans WF, Pusztai L. Selections of patients for endocrine therapies. In: Endocrine
Therapies in Breast Cancer, Chapter 1. Ed(s) A Buzdar. Oxford University Press:
Oxford, 2007, pp. 1-11.
Pusztai L, Symmans WF. Histopathologic and molecular markers of prognosis and
response to therapy. In: Breast Cancer, 2, Chapter 11. Ed(s) K Hunt, GL Robb, EA
Strom, NT Ueno. Springer-Verlag: New York, 2008, pp. 323-343.
Liedtke C, Pusztai L. Pharmacogenetics of breast cancer: Towards the
individualization of therapy. In: Gene expression profiling as an emerging diagnostic
tool to personalize chemotherapy selection for early stage breast cancer, Chapter 6.
Ed(s) B Leyland-Jones. Informa Healthcare: London, 2008, pp. 77-96.
Pusztai L, Sotiriou C. Prognostic and predictive factors in breast cancer. In: Gene
expression profiles, prognosis and prediction of responses to endocrine therapy and
chemotherapy, 2nd. Ed(s) R Walker, A Thompson. Informa Healthcare: London, 2008,
pp. 139-148.
Liedtke C, Pusztai L, Symmans WF. Molecular pathology and transcriptional profiling
in early drug development. In: Molecular Pathology in Drug Discovery and
Development, Chapter 3. Ed(s) S Platero. John Wiley & Sons, Inc.: New Jersey, 2009,
pp. 47-84.
Broom BM, Rinsurongkawong W, Pusztai L, Do KA. Building networks with
microarray data. In: Statistical Methods in Molecular Biology. Ed(s) H Bang, XK
Zhou, HL van Epps, M Mazumdar. Humana Press: New York, 2010, pp. 315-343.
Liedtke C, Gonzalez-Angulo AM, Pusztai L. Definition of triple-negative breast cancer
and relationship to basal-like molecular subtype. In: PPO Updates: Principles and
Practice of Oncology. 24(2). Ed(s) VT DeVita, Jr., TS Lawrence, SA Rosenberg.
Lippincott Williams & Wilkins: New York, 2010, pp. 1-6.
Jeong J, Vannucci M., Do K.A., Broom B, Kim S, Sha N, Tadesse M, Yan K, Pusztai
L. Gene selection for the identification of biomarkers in high-throughout data. In:
60
Lajos Pusztai, M.D., D.Phil
22.
23.
24.
25.
Bayesian Modeling of Bioinformatics, Chapter 9. Ed(s) DK Dey, S Ghosh, B Mallick.
Champman & Hall/CRC Press: USA, 2010, pp. 233-254.
Pusztai L, Yeoh CC. Personalizing treatment selection for breast cancer. In: Molecular
Diagnostics, Chapter 14. Ed(s) H Winther, JT Jorgensen. Pan Stanford Publishing:
Singapore, 2010, pp. 297-323.
Pusztai L, Shiang C, Iwamoto T. Molecular classification of breast cancer. In:
Advanced Therapy of Breast Disease, Chapter 31. Ed(s) Babiera GV, Skoracki RJ,
Esteva FJ. People's Medical Publishing House: USA, 2012, pp. 491-504.
Pusztai L, Kelly CM. Systemic adjuvant therapy for stage I breast cancer. In: Breast
Cancer, a heterogeneous disease entity. The very early stages, Chapter 11. Ed(s) Z
Kahan, T Tot. Springer: Netherlands, 2011, pp. 269-281.
Pusztai L, Shiang C, Iwamoto T. Molecular classification of breast cancer. In:
Advanced Therapy of Breast Disease, 3rd., Chapter 31. Ed(s) Babiera GV, Skoracki RJ,
Esteva FJ, PMPH-USA, 2012.
Books (edited)
26. Pusztai L, Lewis CE, Yap EPH. Cell Proliferation in Cancer. In: Regulatory
mechanisms of neoplastic cell growth. Oxford University Press, 1995.
Invited Editorials and Commentaries
27. Pusztai L., Hortobagyi GN. Discouraging news for high-dose chemotherapy in highrisk breast cancer. Lancet, 1998, 352:501-2.
28. Pusztai L, Hortobagyi GN. High-dose chemotherapy. How resistant is breast cancer?
Drug Resistance Updates, 1998, 1:62-72.
29. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Chemo-signal
therapy, an emerging new treatment modality for cancer. Cancer Treat Rev, 1999,
25:271-7.
30. Pusztai L, Hortobagyi GN. Treatment of early-stage breast cancer. Home HealthCare
Consultant,1999, 6:2-7.
31. Esteva FJ, Pusztai L, Symmans WF, Sneige N, Hortobagyi GN. Clinical relevance of
HER-2 amplification and overexpression in human cancers. Gynecol Oncol, 2000,
7:267-276.
32. Pusztai L, Tanyi J, Hortobagyi GN. Current status of the cytotoxic treatment of breast
cancer. CME Journal of Gynecologic Oncology, 2000, 5:373-381.
33. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery
and assessment. Ann Oncol, 2004, 15(12):1731-7.
34. Pusztai L. Gene expression profiling to predict patient response and outcome in breast
cancer. Advances in Breast Cancer, 2004, 3(5):8-10.
35. Pusztai L. Perspectives and challenges of clinical pharmacogenomics in cancer.
Pharmacogenomics, 2004, 5(5):451-4.
36. Perez EA, Pusztai L, Van de Vijver M. Improving patient care through molecular
diagnostics. Semin Oncol, 2004, 31(5 Suppl 10):14-20.
37. Pusztai L, Gianni L. Prediction of response to preoperative chemotherapy in operable
breast cancer. Nature Clin Practice Onc, 2004, 1:44-50.
38. Hennessy BT, Pusztai L. Adjuvant therapy for breast cancer. Minerva Ginecol, 2005,
57(3):305-26.
61
Lajos Pusztai, M.D., D.Phil
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers
to select preoperative chemotherapy for breast cancer. Breast Cancer, 2005, 12(2):7385.
Rouzier R, Wagner P, Morandi P, Pusztai L. Gene expression profiling of primary
breast cancer. Curr Oncol Rep, 2005, 7(1):38-44.
Pusztai L, Rouzier R, Wagner P, Symmans WF. Individualizing chemotherapy
treatment for breast cancer: Is it necessary, can it be done? Drug Resistance Updates,
2005, 7:325-331.
Pusztai L. Oncogenomics 2005: Dissecting cancer through genome research. IDrugs,
2005, 8(3):215-8.
Esteva FJ, Pusztai L. Optimizing outcomes in HER2-positive breast cancer: The
molecular rationale. Oncology, 2005, 19:5-16.
Pusztai L. Chips to bedside: Incorporation of microarray data into clinical practice.
Clin Cancer Res, 2006, 12(24):7209-14.
Pusztai L., Esteva FJ. Continued use of trastuzumab (herceptin) after progression on
prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest,
2006, 24(2):187-91.
Shih YC, Pusztai L. Do pharmacogenomic tests provide value to policy makers?
Pharmaco Economics, 2006, 24(12):1173-7.
Andre F, Mazouni C, Hortobagyi GN, Pusztai L. DNA arrays as predictors of efficacy
of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and
issues on study design. Biochim Biophys Acta, 2006, 1766:197-204.
Andre F, Pusztai L. Molecular classification of breast cancer: Implications for
selection of adjuvant chemotherapy. Nat Clin Pract Oncol, 2006, 3(11):621-32.
Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of
breast cancer: Limitations and potential. Oncologist, 2006, 11(8):868-77.
Gong Y, Symmans WF, Pusztai L. Gene-expression microarrays provide new
prognostic and predictive tests for breast cancer. Pharmacogenomics, 2007,
8(10):1359-1368.
Pusztai L. Limitations of pharmacogenomic predictor discovery in phase II clinical
trials. Pharmacogenomics, 2007, 8(10):1443-1448.
Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and
predictive tests for breast cancer. Semin Oncol, 2007, 34(2 suppl 3):S10-S16.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Personalized medicine for breast
cancer: Moving forward and going back. Personalized Medicine, 2007, 3(4):363-370.
Pusztai L. The use of microarray technology in the management of breast cancer. Clin
Adv Hematol Oncol, 2007, 5(3):193-197.
Kuerer HM, Wiechman LS, Pusztai L. DCIS of the breast: A look towards discovery
and advancements in the field. Ann Surg Oncol, 2007, 14(11):3033-3034.
Sotiriou C, Pusztai L. Advances in translational research in breast cancer; a bridge to
future therapies. Eur J Cancer, 2008, 44(18):2705-2706.
Pusztai L. Individualized therapy of breast cancer: Are we there yet? Personalized
Medicine, 2008, 5(6):557-559.
Pusztai L. Lost in translation: Prognostic signatures for breast cancer. Nat Clin Pract,
2008, Oncol 5(7):363.
62
Lajos Pusztai, M.D., D.Phil
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Pusztai L, Leyland-Jones B. Promises and caveats of in-silico biomarker discovery. Br
J Cancer, 2008, 99(3):385-386.
Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized
multigene predictors of clinical outcome for breast cancer. Oncologist, 2008,
13(5):477-493.
Pusztai L. Preoperative systemic chemotherapy and pathologic assessment of response.
Pathol Onc Res, 2008, 14(2):169-171.
Sotiriou C, Pusztai L. Gene expression signatures in breast cancer. N Engl J Med,
2009, 360(8):790-800.
Iwamoto T, Coutant C, Bianchini G, Pusztai L. Molecular heterogeneity of estrogen
receptor-positive breast cancer explains variable and contradictory results of
randomized adjuvant chemotherapy trials in breast cancer. AJHO 8(8):386, 2009.
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The
HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist, 2009, 14(4):320-368.
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast
cancer: Current status and future directions. Ann Oncol, 2009, 20(12):1913-1927.
Iwamoto T, Pusztai L. Predicting prognosis of breast cancer with gene signatures: Are
we lost in a sea of data? Genome Med, 2010, 2(11):81.
Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug
resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist
Updat, 2010, 13:99-108, 2010.
Pusztai L, Iwamoto T. Breast cancer prognostic markers in the post-genomic era.
Breast Cancer Res Treat, 2010, 125(3):647.
Pusztai L. Anatomy and biology: Two complementary sides of breast cancer
prognostication. J Clin Oncol, 2011, 29:4347-4348.
Reis-Filho, JS, Pusztai L. Gene expression profiling in breast cancer: Classification,
prognostication, and prediction. Lancet, 2011, 378(9805):1812-1823.
Shiang C, Pusztai L. Molecular profiling contributes more than routine histology and
immonohistochemistry to breast cancer diagnostics. Breast Cancer Res, 2011, 12(Suppl
4)(S6):1-3.
Szekely B, Pusztai L. The value of genomic analysis of breast cancer in drug
development. J Natl Cancer Inst Monogr, 2011, 43:60-62.
Weigelt B, Pusztai L. Ashworth A, Reis-Filho JS. Challenges translating breast cancer
gene signatures into the clinic. Nat Rev Clin Oncol, 2012, 9:58-64.
Abu-Khalaf M., Pusztai L.Influence of genomics on adjuvant treatments for preinvastive and invasive breast cancer. The Breast 22, 2013 S83-S87.
Pusztai L., Hatzis C., Breast Cancer Biomarkers Beyond Molecular Classification.
ASCO Breast Cancer Symposium Daily News 2013, September; 7
Pusztai L. Rouzier R, Symmans WF. CCR 20th Anniversary Commentary: Divide and
Conquer-Breast Cancer Subtypes and Response to Therapy. Clin Cancer Res 2015,
21(16):3575-3577.
Pusztai L: Breast cancer: Chemotherapy and the recurrence score-results as expected?
Nat Rev Clin Oncol. 2015, 12 (12): 690-92.
63
Lajos Pusztai, M.D., D.Phil
78.
79.
80.
81.
Hofstatter E, Mehra K, Yushak M, Pusztai L: Tumor profiling and the incidentalome:
patient decisions and risks. Future Oncol. 2015 Nov 12; 2015 Nov 12. PMID:
26562094.
Pusztai L, Karn T, Safonov A, Abu-Khalad MM, Bianchini G. New Strategies in
Breast Cancer: Immunotherapy. Clin Cancer Res 2016, published online February 11,
2016; doi: 10.1158/1078-0432.CCR-15-1315
Pusztai L, Ladányi A, Székely B, Dank M: [Immunotherapy opportunities in breast
cancer]. Magy Onkol. 2016 Mar 2; 2015 Dec 19. PMID: 26934349\
Sanft T, Pusztai L: Clinical Utility of Biomarker Tests in Decisions on Extended
Endocrine Therapy. J Clin Oncol. 2016 Aug 22; 2016 Aug 22. PMID: 27551119
Abstracts (past 5 years)
82. Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans WF,
Andre F, de The H, Coutant C. Clinical subtype-derived p53 gene signature is
predictive of prognosis and response to chemotherapy in ER-positive but not in ERnegative breast cancers. Cancer Res 69(Suppl 3)(24):863S (#6122), 2009.
83. Iwamoto T, Bianchini G, Coutant C, Shiang CY, Matsuoka J, Symmans WF,
Hortobagyi GN, Simon R, Pusztai L. Different biological processes are associated with
prognosis and chemotherapy sensitivity in the different molecular subtypes of breast
cancer. Cancer Res 69(Suppl 3)(24):864S (#6124), 2009.
84. Dominici LS, Gonzalez VMN, Buzdar AU, Lucci A, Mittendorf EA, Pusztai L,
Krishnamurthy S, Le-Petross HT, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt KK,
Valero V, Kuerer HM. Eradication of axillary node metastases occurs in 74% of
patients receiving neoadjuvant chemotherapy with concurrent trastuzumab for HER2
positive breast cancer. Cancer Res 69(Suppl 3)(24):566S (#1086), 2009.
85. Tabchy A, Symmans WF, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, BarajasFigueroa LJ, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi GN, Pusztai L.
Evaluation of the predictive performance and regimen specificity of a 30-gene predictor
of pathologic complete response in a prospective randomized neoadjuvant clinical trial
for stage I-III breast cancer. Cancer Res 69(Suppl 3)(24):506S (#101), 2009.
86. Pusztai L. Gene expression profiling of breast cancer. Breast Cancer Research
11(Suppl 3):S11, 2009.
87. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Kuerer HM, Pusztai L, Kau SWC,
Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of progression during
neoadjuvant chemotherapy on operative management of breast cancer. Cancer Res
69(Suppl 3)(24):567S (#1090), 2009.
88. Quidville V, Conforti R, Zoubir M, Mathieu MC, Delaloge S, Spielmann M, Dessen P,
Pusztai L, Khayat D, Andre F. Lymphocyte infiltration and interferon response to
predict efficacy of anthracyclines. Ann Oncol 20(Suppl 2):56, 2009.
89. Loi S, Haibe-Kains B, Brown ND, Metallo J, Majjaj S, Desmedt C, Pusztai L, Piccart
M, Esteva FJ, Sotiriou C. Molecular and clinically distinct phenotypes in HER-2
overexpressing breast cancer (HER2+BC) correspond to estrogen receptor status (ER)
status. Ann Oncol 21(Suppl 4):49 (#970), 2009.
90. Pusztai L. Molecular heterogneity of breast cancer: Implications for treatment and
clinical trial design. Breast Cancer Res 11(Suppl 1):S2-S3, 2009.
64
Lajos Pusztai, M.D., D.Phil
91.
Pusztai L. Pharmacogenomic predictive marker discovery in phase II clinical trials:
Mission impossible? Ann Oncol 20(Suppl 2):13, 2009.
92. Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Tutt A, Gillett CE, Piccart M, Phillips
WA, McArthur G, Sotiriou C. PIK3CA AKT1 mutation and HER2 amplification gene
signatures (GS) suggest predominantly negative feedback inhibition of P13K/AKT
pathway in human breast cancer (BC). Ann Oncol 20(Suppl 2):45, 2009.
93. Liedtke C, Ruckert C, Goette M, von Wahlde MK, Kiesel L, Symmans WF, Pusztai L.
Secreted frizzled receptor protein 1 (sFRP-1) as both a potential novel biomarker of
triple negative breast cancer (TNBC), and its sensitivity against taxane/anthracycline
containing neoadjuvant chemotherapy. Cancer Res 69(Suppl 3)(24):722S (#4047),
2009.
94. Bianchini G, Alvarez RH, Qi Y, Hatzis C, Iwamoto T, Shiang C, Coutant C,
Hortobagyi GN, Symmans WF, Pusztai L. The molecular anatomy of breast cancer
stroma: Independent prognostic role in ER-positive and ER-negative cancers. Cancer
Res 69(Suppl 3)(24):507S (#105), 2009.
95. Horak C, Pusztai L, Mudenda B, Xyng G, Trifan O, Saura C, Tseng L-M, Chan S,
Welcher R, Liu D. βIII tubukub expression by immunohistochemistry (IHC) and
mRNA in a randomized phase II neoadjuvant breast cancer (BC) study of Ixabepilone
(ixa) compared to Paclitaxel (pac). Cancer Res 70(Suppl 24):118s (#PD07-02), 2010.
96. Symnmans WF, Hatzis C, Valero V, Booser DJ, Esserman L, Martin M, Vidaurre T,
Holmes F, Souchon EA, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J,
Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K,
Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN Pusztai L. A
genomic predictor of survival following Taxane-Anthracycline chemotherapy for breast
cancer. Cancer Res 70(Suppl 24):118s (#PD07-03), 2010.
97. Pusztai L, Rouzier R, Ibrahim N. A specific nomogram to predict subsquent brain
metastasis in metastatic triple-negative breast cancer patients. J Clin Oncol 27:Suppl S
(#1028), 2010.
98. Santarpia L, Diao L, Baggerly K, Boulbes D, Di Leo A, Calin GA, Symmans WF,
Esteva F, Hortobagyi GN, Pusztai L. Cancer Res. microRNAs and target gene
networks in breast cancer cell lines 70(Suppl 24):259s (#P3-09-03), 2010.
99. Alvarez RH, Bianchini G, Hsu L, Cristofanilli M, Esteva FJ, Pusztai L, Buzdar AU,
Hortobagyi GN, Valero V. Clinical outcome of two sequences of administering
Paclitaxel (P) and Anthracyclines (A) as primary systemic therapy (PST) and adjuvant
chemotherapy (ACT) in breast cancer (BC) patients: A retrospective analysis from the
M. D. Anderson Cancer Center (MDACC). Cancer Res 70(Suppl 24):384s (#P5-10-02),
2010.
100. Loi S, Haibe-Kains B, Lallermand F, Pusztai L, Bardelli A, Gillett C, Ellis P, PiccartGebhart MJ, Phillips WA, McArthur GA, Sotiriou C. Correlation of PIK3CA mutationassociated gene expression signature (PIK3CA-GS) with deactivation of the PI3K
pathway and with prognosis within the luminal-B ER plus breast cancers. J Clin Oncol
27(15):Suppl S (#533), 2010.
101. Andreopoulou E, Hatzis C, Booser D, et al. Correlations of estrogen receptor (ER)
related genomic transcription and ER gene expression with increasing AJCC stage of
ER-positive breast cancer. J Clin Oncol 27(15):Suppl S (#1044), 2010.
65
Lajos Pusztai, M.D., D.Phil
102. Kai K, Saya H, Iwamoto T, Pusztai L, Hortobagyi GN, Ueno NT. Development of a
novel animal model of human triple-negative breast cancer by retroviral oncogene
transduction of mouse mammary stem cells. Cancer Res 70(Suppl 24):147s (#P1-0302), 2010.
103. Mazouni C, Andre F, Broglio K, et al. Estrogen receptor expression and docetaxel
efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized
trials. J Clin Oncol 27(15):Suppl S (#1046), 2010.
104. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, Buzdar A, Martin P,
Kobayashi R, Pusztai L. Evaluation of changes in plasma protein profiles during
neoadjuvant chemotherapy in HER2-positive breast cancer using MALDI-TOF/MS
procedure. Cancer Res 69(Suppl 24):604S (#2037), 2010.
105. Andre F, Dessen P, Job B, Delaloge S, Pusztai L, Lazar V. Functional pathways
analyses to identify candidate therapeutic targets in triple-negative breast cancer. J Clin
Oncol 27(15):Suppl S (#569), 2010.
106. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hamnker L, Gaetje R, Solbach
C, Ahr A, Metzler D, Schmidt M, Mueller V, Holtrich U, Kaufmann M. Identification
of a clinically relevant gene signature in triple negative and basal-like breast cancer.
Cancer Res 70(Suppl 24):90s (#S5-5), 2010.
107. Shen K, Pusztai L, Qi Y, Symmans WF, Song N, Rice SD, Gabrin MJ, O'Shaughnessy
JA, Holmes FA. Multi-gene predictors developed from breast cancer cell lines to
predict response to chemotherapy: A validation study on US Oncology Study 02-103.
Cancer Res 70(Suppl 24):223s (#P2-09-39), 2010.
108. Saura C, Tseng L-M, Chan S, Chacko RT, Campone M, Liu D, Mukhopadhyay J,
Mudenda B, Horak C, Xing G, Pusztai L. Phase II study of Ixabepilone versus
Paclitaxel as neoadjuvant therapy for early stage breast cancer with comparative
biomarker analysis. Cancer Res 70(Suppl 24:118s (#PD07-01), 2010.
109. Caudle AS, Gonzalez-Angulo AM, Kelly HK, Liu P, Pusztai L, Symmans WF, Kuerer
HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor
progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol
27(15):Suppl S (#603), 2010.
110. Pusztai L, Moulder S, Litton J Valero V, Ueno N, Melhem-Bertrandt A, Morrow PK,
Dotter K, Mattair D, Strauss L, Hortobagyi GN, Qi Y, Symmans WF. Prospective
testing of three different gene-signatures for patient selection for Dasatinib therapy in
metastatic breast cancer. Cancer Res 70(Suppl 24):459s (#P6-14-06), 2010.
111. Wang X, Saso H, Iwamoto T, Pusztai L, Hortobagyi GN, Ueno NT. Tazaroteneinduced gene 1 (TIG1) is a novel tumorigenic gene of inflammatory breast cancer.
Cancer Res 70(Suppl 24):372s (#P5-05-05), 2010.
112. Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward WA, Reuben JM,
Hortobagyi GN, Ueno NT. A novel inflammatory breast cancer-specific oncogene,
tazarotene-induced gene 1, promotes tumorigenicity and invasiveness through the
receptor tyrosine kinase axl. Cancer Res 71(Suppl 24):255s (#P2-02-01), 2011.
113. Shiang C, Qi Y, Wang B, Broom B, Pusztai L. ApoE and its receptors (LRP8,
VLDLR) function as growth signals for triple-negative breast cancer and represent a
novel therapeutic target. Cancer Res 71(Suppl 24):414s (#P3-17-01), 2011.
114. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J,
Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L.
66
Lajos Pusztai, M.D., D.Phil
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that
are 1%-10% ER-positive by immunohistochemistry. Cancer Res 71(Suppl 24):191s
(#P1-07-09), 2011.
Thompson AM, Iwamoto T, Jordan L, Purdie C, Bray SE, Baker L, Hardie G, Pusztai
L, Moulder SL, Dewar JA, Hadad SM. Final analysis of the NEOMET trial of
neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway
analysis in primary operable breast cancer. J Clin Oncol 29(15):53s (#534), 2011.
Feugeas J-P, Dumay A, Lehmann-Che J, de Cremoux P, Delord M, Soulier J, Hamy AS, Espie M, Andre F, Marty M, Sotiriou C, Piccart-Gebhart M, Pusztai L, Bertheau P,
de The H. Gene profiling of histopathologically characterized apocrine breast cancers.
Cancer Res 71(Suppl 24):348s (#P3-05-01), 2011.
Kai K, Iwamoto T, Pusztai L, Hortobagyi GN, Saya H, Ueno NT. Identification of
molecular targets for cancer-initiating cells using a triple-negative breast cancer mouse
model. Cancer Res 71(Suppl 24):438s (#P4-03-04), 2011.
Bianchini G, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, Fasolo A, del Conte G,
Santarpia L, Symmans WF, Gianni L. Molecular tumor characteristics influence
adjuvant endocrine treatment outcome. Cancer Res 71(Suppl 24):98s (#S1-7), 2011.
Lousquy R, Delpech Y, Rouzier R, Gligorov J, Hsu L, Barranger E, Pusztai L, Uzan S,
Hortobagyi GN, Coutant C, Ibrahim NK. Nomogram to predict subsequent bone
metastasis in patients with non metastatic breast carcinomas. Cancer Res 71(Suppl
24):291s (#P2-12-06), 2011.
Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM,
Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ,
Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, MericBernstam F. Open label, randomized clinical trial of standard neoadjuvant
chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of
paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptornegative breast cancer (TNBC). J Clin Oncol 29(15):84s (#1016), 2011.
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, Hortobagyi GN,
Pusztai L, Symmans F, Ueno NT. Problems with identifying bone metastasis-specific
genes without considering biological differences between ER-positive and ER-negative
breast cancers. Cancer Res 71(Suppl 24):496s (#P4-16-02), 2011.
Karn T, Pusztai L, Ruckhaeberle E, Liedtke C, Schmidt M, Mueller V, Gaetje R,
Hanker L, Ahr A, Holtrich U, Rody A, Kaufmann M. Prognostic and predictive
predictors for triple negative breast cancer. Cancer Res 71(Suppl 24):124s (#PD03-02),
2011.
Pusztai L, Qi Y, Shi W, Liu C-G, Wang B, Liu X, Booser D, Esteva FJ, Symmans F,
Hortobagyi GN. Protein kinase mutation patterns in human breast cancer. Cancer Res
71(Suppl 24):115s (#S6-4), 2011.
Dumay A, Feugeas J-P, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, de Cremoux
P, Andre F, Sotiriou C, Pusztai L, de The H. TP53 mutation patterns in breast cancer
subgroups. Cancer Res 71(Suppl 24):23s (#P2-02-09), 2011.
Bastien RRL, Ebbert MTW, Boucher KM, Kelly CM, Wang B, Iwamoto T,
Krishnamurthy S, Pusztai L, Bernard PS. Using the PAM50 breast cancer intrinsic
classifier to assess risk in ER+ breast cancers: A direct comparison to Oncotype DX. J
Clin Oncol 29(15):45s (#503), 2011.
67
Lajos Pusztai, M.D., D.Phil
126. Jiang T, Kluger Y, Kulka J, Marcell Szasz A, Pusztai L, Szekely, B. Genomic
alterations in matching primary tumors and metastasis in breast cancer. J Clin Oncol 31,
2013 (suppl; abstr 1549).
127. Hofstatter EW, Lapolt D, Pusztai L, Sorkin M. Clinical experience with exemestane in
postmenopausal women at increase risk of breast cancer. J Clin Oncol 31, 2013 (suppl;
abstr 1565).
128. Delpech Y; Fraser Symmans W, Jiang T, Natowicz R, Pustai L, Qi Y, Shi W.
Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity
in breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 532).
129. Alvarez RH, Avritscher R, Burton EM, Chavez-MacGregor M, Gonzales-Angulo AM,
Meric-Bernstam F, Hortobagyi GN, Mattair D, Moulder, SL, Murray JL, Pusztai L,
Sahin AA, Santiago L, Symmans WF, Ueno NT, Valero V. Breast cancer evaluation
and targeted investigational therary (BEAT-IT): A pilot prospective tissue testing to
guide clinical trial selection. J Clin Oncol 31, 2013 (suppl; abstr 532).
130. Beamish R, Crown J, Gonzalez-Angulo AM, Keating Litton J, Kelly, Catherine M,
Kelly Ciara M, McCaffrey J, McGee SF, Moylan EJ, O’Connor M, O’Reilly S, Pusztai
L, Smith M, A comparataive analysis of distant recurrence risk assessments by
Oncotype DX recurrence score alone and integrated with clinicopathologic factors in
early-stage breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 598).
131. Abraham G, Abu-Khalaf M Capiello M, Chmael S, Chung G, Clark MB, DiGiovanna
M, Harris L, Hofstatter EW, Israel GM, James SJ, Lilian R, Pusztai L, Sanft TB,
Sowers N. Phase I study of the HDAC inhibitor vorinostat in combination with
capecitabine in a biweekly schedule in advanced breast cancer. J Clin Oncol 31, 2013
(suppl; abstr 2587).
132. Symmans WF, Wei C., Gould R., Zhang Y., Hunt KK,, Bucholz TA,, Valeo V,,
Hortobagyi G.N,, Pusztai L.. Long Term prognostic value of residual cancer burden
(RCB) classification following neoadjuvant chemotherapy. San Antonio Breast Cancer
Symposium, Cancer Res 2013;73(24 Suppl): Abstract S6-02.
133. Shi W., Balazs B., Qi Y., Gyorffy B., Wang B., Liu C-G, Shiang CY., Valeo V.,
Moulder-Thom;pson S., Avritscher R., Powis G., Hortobagyi GN., Natowicz R., Wali
V., Weinstein J., Symmans WF, Pusztai L.. Combined analysis of gene expression,
DNA copy number and mutation profiling data to display biological process anomalies
in individual cancers. San Antonio Breast Cancer Symposium, Cancer Research
2013:73(24 Suppl): Abstract (PD4-6)
134. Rimm DL, Hollmes E., Schalper K., Bradbury I., Zarella E., Ellis C., Baselga J.,
Eidtmann H., Piccart M., Habeck N., Pusztai L., Perez E.. EGFR expression is
associated wih decreased response from HER2 targeted therapeutics in the neoadjuvant setting in the NeoALTTO trial. San Antonio Breast Cancer Symposium
Abrtract nr. P1-08-09 Cancer Research 2013;73 (24Suppl)
135. Scaltriti, Nuciforo P., Bradbury I., Sperinde J., Serra V., Parra J., Prudkin L., Harbeck
N., Pusztai L., Ellis C., Eidtmann H., Arribas J., Piccart M., Baselga J.. High HER2
expression correlates with response to trastuzumab and the combination of trastuzumab
and lapatinib in the Neo ALTO phase III trail. AACR Conference, Cancer Research
2013;73(24 Suppl): Abstract nr P1-08-42
136. Jeselsohn R., Yelensky R., Buchwalter G., Frampton G., Meric-Bernstam F.,
Cristofanilli M., Arteaga C., Balko J., Gilmore L., Schnitt S., Come S., Pusztai L.,
68
Lajos Pusztai, M.D., D.Phil
137.
138.
139.
140.
141.
142.
131.
132.
133.
134.
135.
Stephens P., Miller V., Brown M.. AACR 104th Annual Meeting 2013 Washington
DC, Cancer Research 2013;73(24 Suppl): Abstract nr S3-06. PMCID:PMC3842438
Gyorffy B., Karn T., Sztupinszki Z., Weltz B., Vuller v., Pusztai L.. Classification
using dynamic re-discovery of the strongest prognostic features in each analysis
outperforms static gene expression signatures for prognostic prediction in breast cancer.
AACR 104th Annual Meeting 2013, Washington DC. Cancer Research 2013:73(24
Suppl): Abstract P3-05-05.
Shi W., Gong A., Jian T., Natowicz R., Pusztai L.. Metabolic vulnerability of breast
cancer based on shifts in the expression of metabolic enzyme isoforms. AACR 104th
Annual Meeting 2013 Poster Presentation, Cancer Research 2013; volume 73, Issue 8
Supplement 1, Abstract 1899.
Wimberly H., schalper K., chen L., Velcheti V., Pusztai L., Rimm D.. PD-L1 protein
expression is a prognostic biomarker in breast cancer. AACR 104th Annual Meeting,
Cancer Research 2013;73(24 Suppl): Abstract )2-10-02.
Liedtke C., Karn T., Gluz O., Becker S., Pusztai L., Holtrich U., Rody A.. Systematic
analysis of molecular subgroups and age in patrients with breast cancer. AACR 104th
Annual Meeting, Cancer Research 2013;73(24 Suppl): Abstract P4-04-06
Wang X., Saso H., Iwamoto T., Xia W., Gong Y, Pusztai L., Woodward W., Reuben
J., Hortobagyi G., Hung M., Ueno N.. Tazarotene-induced gene 1 promotes
tumorigenicity and invasiveness of inflammatory breast cancer through receptor
tyrosine kinase Axl. Poster Presentation AACR 104th Annual Meeting 2013
Washington DC. Cancer Research, 2013 Volume 73 Issue 8, Supplement 1
Bianchini G., Rossi CM., Iwamoto T., Kam T., Callari M., Kelly CM., Pusztai L.,
Gianni L.. Expression of immune checkpoint released genes are prognostic in
untreated breast cancer. San Antonio Breast Cancer Symposium Cancer Res
2013;73(24 Suppl): Abstract P2-11-04
Jiang T., Shi W., Ononye S., Han G., Wali V., Pusztai L., Hatzis C..
Transcriptionalheterogeneity correlates with chemotherapy sensitivity in triple negative
breast cancer and varies by molecular subtype. San Antonio Breast Cancer
Symposium, Cancer Research 2013:73(24Suppl): Abstract P4-06-05
Hofstatter E., Lannin D., Horowitz N., Killelea B., Tsangaris T., Pusztai L., Chung G.,
Sanft T., DiGiovanna M., Abu-Khalaf M., Mougalian S., Chagpar A.. Richer and wiser:
Factors correlated with chemoprevention use in the United States. San Antonio Breast
Cancer Sympoisum 2013 P5-13-05
Schalper KA., Velcheti V., Winberly H., Carvajal D., Pusztai L., Rimm DL.. Epithelial
expression of Pd-L1 mRNA is associated with increased TILs and better outcome in
breast carcinomas. San Antonio Breast Cancer Symposium P6-05-19
Abu-Khalaf M., Medic I., Hatzis C., Park E., Chung G., DiGiovanna M., Hofstatter E.,
Sanft T., Pusztai L., Gross C., Russell K., Russell R.. Baseline assessment of left
ventricular function for breast cancer patients undergoing anthracycline and/or
tastuzumab: What is the prevalence of baseline dysfunction? San Antonio Breast
Cancer Symposium, Cancer Research 2013;73(24 Suppl): Abstract P6-06-09
Hatzis C., Gould RE., Zhang Y., Abu-Khalaf M., Chung G., Sanft T., Hofstatter E.,
DiGiovanna M., Shi W., Chagpar A., Symmans WF., Pusztai L.. Predicting
improvements in survival based on improvements in pathologic response rate to
69
Lajos Pusztai, M.D., D.Phil
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
neoadjuvant chemotherapy in different breast cancer subtypes. San Antonio Breast
Cancer Symposium, Cancer Research 2013;73(24 Suppl): Abstract P6-06-37
Huelsewig C., Bernemann c., Ruchert C., Kiesel L., Goette M., Rody A., Pusztai L.,
Hempel G., Liedtke C.. Secreted frizzled related protein 1 (SFRP1) as potential
regulator of chemotherapy response for patrients with triple negative breast cancer
(TNBC) AACR San Diego 2014 PO.CL11.05
Fuentes-Mattei E., Velazquez-Torres G., Phan L., Zhang F., Chou P., Shin J., Choi H.,
Chen J., Zhao R., Chen J., Gully c., Carlock C., Qu Y., Zhang Y., Wu Y., Esteva F.,
Luo Y., McKeehan W., Ensor J., Hortobagyi G., Pusztai L., Fraser-Symmans W., Lee
M., Yeung C.. Obesity induces changes in adipokines profile and activate Akt/mTOR
signaling accelerating breast carcinogenesis and tumor growth. ACCR San Diego 2014
PO. TB01.07 Cancer Res 2013;73(24 Suppl): Abstract nr P3-01-04
Gyorffy B., Karn t., Sztupinszki Z., Weltz b., Muller v., Pusztai L.. Application of a
dynamic retraining for each patient using case-specific training cohorts to predict
survival in breast cancer patients. ASCO Chicago J Clin Oncol 32:5s, 2014 (suppl;
abstr 1065)1065
Bianchini G., Rossi G., Callari M., Iwamoto T., Galeota E., Karn T., Kelly C.,
Zambetti M., Santarpia L., Pusztai L., Gianni L.. An immune-related signature for
prediction of risk of late recurrences beyond proliferation and ER-related genes in ERpositive breast cancer. ASCO Chicago, J Clin Oncol 32:5s, 2014 (suppl; abstr 530)
Jhaveri A., Abu-Khalaf M., DiGiovanna M., Pusztai L., Hofstatter E., Sanft T., Sowers
N., Lurie B., Silber A., Brandt D., Hochster H., Lacy J., Stein S., Chung G.. Pilot study
of sorafenib and biweekly capecitabine in patients with advance breast and
gastrointestinal tumors. ASCO Chicago J Clin Oncol 32:5s, 2014 (suppl; abstr 2561)
Nanda R., Plimack E., Dees E., Gupta S., Berger R., Elfiky A., Pusztai L., Buisseret L.,
Geva R., Pai S., Pathiraja K., Iannone R., Gause C., Brown H., Houp H., Cheng J.,
Chow L.. A [phase lb multicohort study of MK-3475 in patients with advanced solid
tumors. ASCO Chicago J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3119)
Jaing T., Shi W., Symmans W., Li C., Platt J., Wali V., Lifton R., Pusztai L., Hatzis C..
Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy
in triple negative breast cancer. San Antonio Breast Cancer Symposium 2014 PD 3-2
Shi W., Chagpar A., Jiang T., Lannin D., Killelea B., Horowitz N., Lim R., Platt J., Ng
CKY, Wali V., Weigelt B., Reis-Filho J., Hatzis C., Pusztai L.. Reliability of whole
exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies.
San Antonio Breast Cancer Symposium 2014 PD 3-4
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart
M, Emancipator K, Gonzalez EJ, Houp J, Pathiraja K, Karantza V, Iannone R, Gause
CK, Cheng JD, Buisseret L. A phase Ib study of pembrolizumab (MK-3475) in
patients with advanced triple-negative breast cancer. San Antonio Breast Cancer
Symposium 2014 General Session 1 S1-09
Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V,
Fountzilas G, Rimm D.. Measurement of domain-specific HER2 (ERBB2) expression
classifies benefit from Trastuzumab in breast cancer. San Antonio Breast Cancer
Symposium 2014 Poster Session 3 P3-06-26
Chagpar AB, Mougalian S, Lannin D, Abu-Khalaf M, Killelea B, Sanft T, Pusztai L..
Trends in clinicopathologic features and systemic therapy use in breast cancer patients:
70
Lajos Pusztai, M.D., D.Phil
147.
148.
149.
150.
151.
152.
153.
154.
156.
157.
158.
Findings from the National Cancer Database. San Antonio Breast Cancer Symposium
2014 Poster Session 3 P3 07-11
Yang VQ, Han G, Mougalian SS, Killelea BK, Horowitz N, Chagpar AB, Hayse B,
Pusztai L, Lannin D.. Predictors of complete pathological response to neoadjuvant
chemotherapy for breast cancer: 19,310 cases from the national cancer database treated
in 2010 and 2011. San Antonio Breast Cancer Symposium 2014 Poster Session 3 P3
11-02
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Perez EA, Sikov WM,
Chennuru S, Mirshahidi H, Vidito S, Lew DL, Pusztai L, Livingston RB, Hortobagyi
GN.. S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with
or without bevacizumab in treating women with inflammatory or locally advanced
breast cancer (NCI CDR0000636131) San Antonio Breast Cancer Symposium 2014
Poster Session 3 P3 11-16
Forero A, Burris III H, LoRusso P, Specht J, Miller K, Mita M, Liu MC, Modi S,
Pusztai L, Sussman D, Kostic A. SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1-positive breast cancer. OT2 3-01
Abu-Khalaf M, Mayer I, Litten JB, Raponi M, Allen AR, Pusztai L, Arteaga CL.
A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral
lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway.
Bianchini G, Galeota E, Jiang T, Callari M, Zambetti M, Iwamoto T, Karn T, Hatzis C,
Pusztai L, Gianni L.. The heterogeneous clinical behavior of luminal breast cancers is
associated with different mutational landscapes. San Antonio Breast Cancer
Symposium 2014 Poster Session P2-03-05
Karn T, Pusztai L, Liedtke C, Bianchini G, Györffy B, Hatzis C, Rody A, Müller V,
Schmidt M, Holtrich U, Becker S.. Gene expression associated with poor prognosis of
young TNBC patients. San Antonio Breast Cancer Symposium 2014 Poster Session
P2-05-04
Safonov A., Shi W., Platt J., Aktas B., Kurita T., Pusztai L., Hatzis C.. A framework to
assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental
Cost Effectiveness Ratio (TICER). American Society Clinical Oncology 2015 Poster
Session #178, Journal Clincal Oncology 33
Hofstatter E., Yushak M., Bouberhan S., Han G., Epstein L., Pusztai L.. Discovery and
disclosure of incidental genetic information obtained through high throughput
sequencing. American Society Clincial Oncology 2015 Poster Session abstract e17779,
J Clinical Oncology 33, 2015
Timms K., Chagpar A., Wali V., Bossuyt V., Reid J., Gutin A., Neff C., Hofstatter E.,
Lanchbury J., Pusztai L.. Reproducibility of homologous recombination deficiency
(HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. American
Society Clincial Oncology ASCO Annual Meeting 2015 Poster Session #205 Journal
Clincial Oncology 33 (abstr 1091)
Mougalian S., Long J., Hall J., Adelson K., Abu-Khalaf M., Pusztai L., Gross C.
Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.
Journal of Clinical Oncology, ASCO Annual Meeting 2015 Poster Session#123
(Abstract 1008)
Sanft T., Aktas B., Schroeder B., Bossuyt V., DiGiovanna M., Abu-Khalaf M.,
Chung G., Silber A., Hofstatter E., Mougalian S., Epstein L., Hatzis C.,
71
Lajos Pusztai, M.D., D.Phil
159.
160.
161.
162.
162.
163.
164.
Schnabel C., Pusztai L. Prospective study of the decision-making impact of the
Breast Cancer Index in the selection of patients with ER+ breast cancer for
extended endocrine therapy. Journal of clinical Oncology, ASCO Annual
Meeting 2015, Abstract #58, Poster #26
Patel J., Reiner E., Bossuyt V., Epstein L., Platt J., DiGiovanna M., Chung G.,
Silber A., Sanft T., Hofstatter E., Mougalian S., Abu-Khalaf M., Gershkovich
P., Hatzis C., Pusztai L. Mutation-based treatment recommendations from
next generation sequencing data: A comparison of web-tools, Journal Clinical
Oncology, ASCO Annual Meeting 2015, Abstract #e12564
Thompson A., Hadad S., Jordan L., Roy P., Purdie C., Iwamoto T., Pusztai L.,
Moulder S., A prospective comparision of ER, PR, Ki67 and gene expression in
paired sequential core biopsies of primary, untreasted breast cancer. Journal of
Clinical Oncology 33, ASCO Annual meeting 2015, Poster #66 (suppl; abstr
578)
Abu-Khalaf A., Mayer I., Tankersley C., Moy J., Allen A., Vogel C., Holmes F.,
Nanda R., Miller K., Patel R., Pusztai L., Arteaga C. A phase 2, randomized,
open-label study of lucitanib in patients with FGF aberrant metastatic breast
cancer. Journal of Clinical Oncology 33, ASCO Annual Meeting 2015, Poster
#115b, Abstract TPS628
Bianchini G., Callari M., Iwamoto T., Riba M., Vigano L., Locatelli A., Zambetti M.,
Karn T., Pusztai L., Gianni L., Contribution of immune system and tumor-related
interferon signaling to epirubicin response in triple-negative (TN) breast cancers.
ASCO Annual Meeting 2015, Journal of Clinical Oncology 33, 2015, Poster 1081,
Abstract 1081.
Chagpar A., Killelea B., Tsangaris T., Butler M., Stavris K., Yao X., Li F.,
Bossuyt V., Pusztai L, Horowitz N. Can routine cavity shave margins (CSM)
imprive local control in breast cancer? Intitial results of the SHAVE trial, a
prospective randomized control trial of routine CSM vs., standard partial
mastectomy (SPM). Journal of Clinical Oncology 33, ASCO Annual Meeting
2015 Poster #126, Abstract 1012.
Chavez-Mac Gregor M., Barlow W., Pusztai L., Goetz M., Rastogi P., Ganz P.,
Mamounas E., Paik S., Bandos H., Gralow J., Lew D., Hortobagyi G., Phase III
randomized, placebo-controlled clinical trial evaluating the use of adjuvant
endocrine therapy +/-one year of everolimus in patients with high-risk, hormone
receptor (HR) positive and HER2-negative breast cancer (BC):
SWOG/NRG/Alliance S1207 (NCT01674140). Journal of Clinical Oncology
ASCO Annual Meeting 2015, Poster #120a, Abstract PS637.
Abu-Khalaf A., Mougalian S., Sanft T., Hofstatter E., Chung G., Adelson K.,
Silber A., Brandt D., Bober-Sorcinelli K., Kidwai W., Sabbath K., DiGiovanna
M., Sikov W., Pusztai L. A phase II trial of neoadjuvant aromatase inhibitor
therapy and the mTOR inhibitor everolimus in postmenopausal women with
hormone receptor positive/HER2 negative breast cancer and a low/intermediate
risk Oncotype Dx Recurrence Score (< 25). Journal of Clinical Oncology 2015
ASCO Annual Meeting Poster #116b, (Abstract TPS630)
72
Lajos Pusztai, M.D., D.Phil
Manuals, Teaching Aids, Other Teaching Publications
Pusztai L, Hortobagyi GN. Internet-based CME program on breast cancer treatment
maintained by Medical Directions Inc. (www.vlh.com), 1999.
Pusztai L. Medical management of breast cancer. A teaching manual for sales representatives
of Novartis Pharmaceuticals commissioned by Medical Directions, Inc. 1999.
Ruggeri A, Pusztai L. Self-assessment in oncology. 38, 25. Breast Cancer Review Questions,
Hospital Physician, 2002.
Pusztai L. Role of genomics and emerging novel molecular diagnostic tests in the routine
management of early-stage breast cancer. 1(1). Ed(s) Peck, S. Clinical Advances in
Breast Cancer: Dallas, 8-11, 2008.
Pusztai, L. Experts Perspective: Personalized Medicine in the 21st Century. Internet based
online medical education site: Advances in Oncology for Community-based
Oncologists (http://www.oncdoccme.com/index.php), 2010.
Letters to the Editor
1.
Rutgers EJ, Pusztai L, Bernards R. Are short-term or long-term recurrence rates more
important in breast cancer screening? Ann Intern Med 149(5):357, 2008.
Patents and Technology Licenses
Board of Regents, The University of Texas System, Pusztai L. Methods and composition for the
identification, assessment and therapy of human cancers, United States, 09/733,853,
6/13/2002, Issued
Millennium Pharmaceuticals, Inc., Compositions, kits, and methods for identification,
assessment, prevention, and therapy of breast cancer, United States, 60/299,887,
1/16/2003, Issued
Board of Regents, The University of Texas System co-owns with Bristol Myers Squibb Co.,
Pusztai L, Symmans WF, Hess KR, Ayers MD, Stec JJ. Affymetrix gene chip multigene
predictors of response to preoperative chemotherapy, United States, 10/955,054,
9/30/2004, Issued
Board of Regents, The University of Texas System co-owns with Millennium Pharmaceuticals,
Pusztai L, Symmans FW, Hess KR, Ayers M, Stec J. Multigene predictors of response to
chemotherapy, United States, 60/575,308, 12/15/2005, Issued
Board of Regents, The University of Texas System co-owns with Nuvera Biosciences, Symmans
WF, Hatzis C, Anderson K, Pusztai L. Calculated index of genomic expression of estrogen
receptor (ER) and ER-related genes, United States, 11/530,785, 9/11/2006, Issued
Board of Regents, The University of Texas System co-owns with Nuvera Biosciences, Hatzis C,
Symmans FW, Pusztai L. Method of measuring residual cancer and predicting patient survival,
United States, 11/786,980, 4/13/2007, Issued
73
Lajos Pusztai, M.D., D.Phil
Board of Regents, The University of Texas System, Hatzis C, Symmans WF, Pusztai L.
Bifunctional predictors of cancer treatment sensitivity and resistance, United States,
PCT/US2007/083651, 6/19/2008, Issued
Board of Regents, The University of Texas System co-owns with Nuvera Biosciences, Hatzis C,
Symmans WF, Pusztai L. Genetic markers for cancer outcomes from biomodal expression
behavior, United States, 61/077,541, 7/2/2008, Issued
Board of Regents, The University of Texas System, Symmans WF, Pusztai L, Hatzis C.
Predictors of chemotherapy response based on endpoints related to residual cancer burden after
treatment, United States, 61/020,292, 1/10/2008, Filed
Board of Regents, The University of Texas System co-owns with Nuvera Biosciences, Symmans
WF, Pusztai L. Index of genomic expression of estrogen receptor (ER) and ER-related genes,
United States, 61/174,706, 5/3/2010, Filed
Board of Regents, The University of Texas System, Ueno NT, Wang X, Pusztai L. Methods and
compositions related to Tazarotene-induced gene 1 (TIG1), United States, 61/420,670,
12/7/2010, Filed
74